<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03823378</url>
  </required_header>
  <id_info>
    <org_study_id>M16-763</org_study_id>
    <secondary_id>2018-002306-31</secondary_id>
    <nct_id>NCT03823378</nct_id>
  </id_info>
  <brief_title>A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib</brief_title>
  <official_title>A Phase 2, Multicenter, Double-Blind, Parallel Group Long Term Extension Study in Rheumatoid Arthritis Subjects Who Have Completed a Preceding Phase 2 Randomized Controlled Trial With ABBV-105 Given Alone or in Combination With Upadacitinib (ABBV-599)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a long-term extension (LTE) study to assess the safety, tolerability, and efficacy&#xD;
      of ABBV-105 (elsubrutinib [ELS]) and ABBV-599 (ELS 60 mg and upadacitinib [UPA] 15 mg) in&#xD;
      participants with rheumatoid arthritis (RA) who completed Study M16-063 (NCT03682705).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a Phase 2, double-blind, multicenter, long-term extension (LTE) study to assess the&#xD;
      safety, tolerability, and efficacy of 3 doses of ABBV-105 (elsubrutinib [ELS] 5 mg, 20 mg,&#xD;
      and 60 mg) and ABBV-599 (ELS 60 mg and upadacitinib [UPA] 15 mg) in adults with active&#xD;
      rheumatoid arthritis with inadequate response or intolerance to biologic disease-modifying&#xD;
      antirheumatic drugs (bDMARDs). Participants who successfully completed treatment in the&#xD;
      feeder Study M16-063, a Phase 2 dose exploratory study, were eligible to participate in this&#xD;
      study. Those who met eligibility criteria and entered this study receiving ELS, ABBV-599, or&#xD;
      UPA from Study M16-063 continued on their previously assigned treatment through termination&#xD;
      of this study. Participants originally randomized to placebo in Study M16-063 rolled over to&#xD;
      ABBV-599 in a blinded fashion in this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study M16-763 was terminated early as the benefit of each treatment arm from the feeder study&#xD;
    (Study M16-063) did not provide appreciable evidence of differentiated clinical effect to&#xD;
    warrant further long-term continuation.&#xD;
  </why_stopped>
  <start_date type="Actual">May 13, 2019</start_date>
  <completion_date type="Actual">September 9, 2020</completion_date>
  <primary_completion_date type="Actual">September 9, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>On or after the first dose of study drug in Study M16-763, and up to 30 days after the last dose of study drug in Study M16-763, up to 52 weeks</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug as either having a reasonable possibility or no reasonable possibility. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Disease Activity Score 28 C-reactive Protein (DAS28-CRP) From Baseline of Study M16-063 at Each Study Visit in Study M16-763</measure>
    <time_frame>Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763</time_frame>
    <description>The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from Baseline indicates improvement in disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Low Disease Activity (LDA) Based on Disease Activity Score 28 C-reactive Protein (DAS28-CRP)</measure>
    <time_frame>Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763</time_frame>
    <description>The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. Low Disease Activity (LDA) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) of less than or equal to 3.2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Clinical Remission (CR) Based on Disease Activity Score 28 C-reactive Protein (DAS28-CRP)</measure>
    <time_frame>Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763</time_frame>
    <description>The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. Clinical Remission (CR) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) of less than 2.6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Disease Activity Index (CDAI) From Baseline of Study M16-063</measure>
    <time_frame>Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763</time_frame>
    <description>The CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. A negative change from Baseline indicates improvement in disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Low Disease Activity (LDA) Based on Clinical Disease Activity Index (CDAI) Criteria</measure>
    <time_frame>Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763</time_frame>
    <description>The CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. Low Disease Activity (LDA) based on CDAI is defined as achieving a total CDAI score of less than or equal to 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Clinical Remission (CR) Based on Clinical Disease Activity Index (CDAI) Criteria</measure>
    <time_frame>Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763</time_frame>
    <description>The CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. Complete Remission (CR) based on CDAI is defined as achieving a total CDAI score of less than or equal to 2.8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response</measure>
    <time_frame>Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763</time_frame>
    <description>Participants who met the following 3 conditions for improvement from baseline of Study M16-063 were classified as meeting the American College of Rheumatology 20% response (ACR20) criteria:&#xD;
≥ 20% improvement in 68-tender joint count from Baseline of Study M16-063&#xD;
≥ 20% improvement in 66-swollen joint count from Baseline of Study M16-063 and&#xD;
≥ 20% improvement in at least 3 of the 5 following parameters from Baseline of Study M16-063:&#xD;
Patient's Assessment of Pain (Visual Analog Scale [VAS])&#xD;
Patient's Global Assessment of Disease Activity (PtGA)&#xD;
Physician's Global Assessment of Disease Activity (PhGA)&#xD;
Health Assessment Questionnaire Disability Index (HAQ-DI)&#xD;
High-sensitivity C-reactive protein (hsCRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response</measure>
    <time_frame>Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763</time_frame>
    <description>Participants who met the following 3 conditions for improvement from baseline of Study M16-063 were classified as meeting the American College of Rheumatology 50% response (ACR50) criteria:&#xD;
≥ 50% improvement in 68-tender joint count from Baseline of Study M16-063&#xD;
≥ 50% improvement in 66-swollen joint count from Baseline of Study M16-063 and&#xD;
≥ 50% improvement in at least 3 of the 5 following parameters from Baseline of Study M16-063:&#xD;
Patient's Assessment of Pain (Visual Analog Scale [VAS])&#xD;
Patient's Global Assessment of Disease Activity (PtGA)&#xD;
Physician's Global Assessment of Disease Activity (PhGA)&#xD;
Health Assessment Questionnaire Disability Index (HAQ-DI)&#xD;
High-sensitivity C-reactive protein (hsCRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response</measure>
    <time_frame>Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763</time_frame>
    <description>Participants who met the following 3 conditions for improvement from baseline of Study M16-063 were classified as meeting the American College of Rheumatology 70% response (ACR70) criteria:&#xD;
≥ 70% improvement in 68-tender joint count from Baseline of Study M16-063&#xD;
≥ 70% improvement in 66-swollen joint count from Baseline of Study M16-063 and&#xD;
≥ 70% improvement in at least 3 of the 5 following parameters from Baseline of Study M16-063:&#xD;
Patient's Assessment of Pain (Visual Analog Scale [VAS])&#xD;
Patient's Global Assessment of Disease Activity (PtGA)&#xD;
Physician's Global Assessment of Disease Activity (PhGA)&#xD;
Health Assessment Questionnaire Disability Index (HAQ-DI)&#xD;
High-sensitivity C-reactive protein (hsCRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Swollen Joint Count 66 (SJC66) From Baseline of Study M16-063</measure>
    <time_frame>Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763</time_frame>
    <description>Sixty-six joints were assessed for swelling by physical examination. Swelling of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with swelling) to 66 (worst possible score/66 joints with swelling). Negative values indicate improvement from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tender Joint Count 68 (TJC68) From Baseline of Study M16-063</measure>
    <time_frame>Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763</time_frame>
    <description>Sixty-eight joints were assessed for tenderness by physical examination. Pain or tenderness of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with tenderness) to 68 (worst possible score/68 joints with tenderness). Negative values indicate improvement from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Participant's Assessment of Pain (Visual Analog Scale [VAS]) From Baseline of Study M16-063</measure>
    <time_frame>Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763</time_frame>
    <description>Participants rated their pain on a visual analogue scale (VAS) of 0 to 100 (mm), with 0 representing no pain and 100 representing the worst possible pain. Negative values indicate improvement from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient's Global Assessment of Disease Activity (PtGA) From Baseline of Study M16-063</measure>
    <time_frame>Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763</time_frame>
    <description>Participants rated their disease activity for the past 24 hours using a Patient's Global Assessment of Disease Activity Global visual analogue scale (VAS). The range is 0 to 100 mm, with 0 representing no disease activity and 100 representing severe disease activity. Negative values indicate improvement from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physician's Global Assessment of Disease Activity (PhGA) From Baseline of Study M16-063</measure>
    <time_frame>Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763</time_frame>
    <description>The physician assessed a participant's disease activity at the time of the visit using a Physician's Global Assessment of Disease visual analogue scale (VAS). The range is 0 to 100 mm, with 0 representing no disease activity and 100 representing severe disease activity. Negative values indicate improvement from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Health Assessment Questionnaire Disability Index (HAQ-DI) From Baseline of Study M16-063</measure>
    <time_frame>Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763</time_frame>
    <description>The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from baseline in the overall score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in High-Sensitivity C-Reactive Protein (Hs-CRP) From Baseline of Study M16-063</measure>
    <time_frame>Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763</time_frame>
    <description>C-reactive protein is a blood test marker for inflammation in the body, and levels rise in response to inflammation. A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Morning Stiffness Severity From Baseline of Study M16-063</measure>
    <time_frame>Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763</time_frame>
    <description>Morning stiffness severity was assessed by a numeric rating-scale (NRS). Participants rated the severity of morning stiffness during the past week from 0 to 10 with 0 representing &quot;not severe&quot; and 10 &quot;very severe&quot;. Negative values indicate improvement from baseline.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Rheumatoid Arthritis (RA)</condition>
  <arm_group>
    <arm_group_label>ABBV-599 in M16-063/ABBV-599 in M16-763</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABBV-105 60 mg/UPA placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABBV-105 20 mg/UPA placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABBV-105 5 mg/UPA placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UPA 15 mg/ABBV-105 placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks; placebo capsule for elsubrutinib once a day by mouth for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in M16-063/ABBV-599 in M16-763</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo in M16-063; 60 mg elsubrutinib capsule once a day by mouth for 48 weeks and 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks in M16-763</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elsubrutinib</intervention_name>
    <description>Elsubrutinib capsule will be administered orally.</description>
    <arm_group_label>ABBV-105 20 mg/UPA placebo</arm_group_label>
    <arm_group_label>ABBV-105 5 mg/UPA placebo</arm_group_label>
    <arm_group_label>ABBV-105 60 mg/UPA placebo</arm_group_label>
    <arm_group_label>ABBV-599 in M16-063/ABBV-599 in M16-763</arm_group_label>
    <arm_group_label>Placebo in M16-063/ABBV-599 in M16-763</arm_group_label>
    <other_name>ABBV-105</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Upadacitinib</intervention_name>
    <description>Upadacitinib tablet will be administered orally.</description>
    <arm_group_label>ABBV-599 in M16-063/ABBV-599 in M16-763</arm_group_label>
    <arm_group_label>Placebo in M16-063/ABBV-599 in M16-763</arm_group_label>
    <arm_group_label>UPA 15 mg/ABBV-105 placebo</arm_group_label>
    <other_name>ABT-494</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for elsubrutinib</intervention_name>
    <description>Placebo capsule for elsubrutinib will be administered orally.</description>
    <arm_group_label>UPA 15 mg/ABBV-105 placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for upadacitinib</intervention_name>
    <description>Upadacitinib placebo tablet will be administered orally.</description>
    <arm_group_label>ABBV-105 20 mg/UPA placebo</arm_group_label>
    <arm_group_label>ABBV-105 5 mg/UPA placebo</arm_group_label>
    <arm_group_label>ABBV-105 60 mg/UPA placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant has completed Study M16-063&#xD;
&#xD;
          -  Participant has not developed any laboratory or clinical discontinuation criteria as&#xD;
             defined in the Study M16-063 protocol&#xD;
&#xD;
          -  Participant is willing and/or able to comply with procedures required in the current&#xD;
             study protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant is currently enrolled or planning to enroll in another interventional&#xD;
             clinical study while participating in this study (except the preceding study M16-063)&#xD;
&#xD;
          -  Participant requires vaccination with any live vaccine during study participation,&#xD;
             including at least 30 days after the last dose of study drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint Luc /ID# 207719</name>
      <address>
        <city>Woluwe-Saint-Lambert</city>
        <state>Bruxelles-Capitale</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven /ID# 207722</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Research Assoc /ID# 207769</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5M 0H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manitoba Clinic /ID# 206852</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1M3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIADS Research Co Ltd /ID# 206853</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3N 0K6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hosp.-Toronto /ID# 206851</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Latha Naik /ID# 213440</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7K 3H3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatolog s.r.o. /ID# 209941</name>
      <address>
        <city>Jihlava 1</city>
        <state>Jihlava</state>
        <zip>586 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologicky ustav Praha /ID# 209943</name>
      <address>
        <city>Prague 2</city>
        <state>Praha 2</state>
        <zip>128 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologie MUDr. Klara Sirova /ID# 209944</name>
      <address>
        <city>Ostrava</city>
        <zip>702 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCR Czech a.s /ID# 209942</name>
      <address>
        <city>Pardubice</city>
        <zip>530 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRU Hungary Egeszsegugyi és Szolgaltato Kft. /ID# 208186</name>
      <address>
        <city>Miskolc</city>
        <state>Borsod-Abauj-Zemplen</state>
        <zip>3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szabolcs-Szatmar-Bereg Megyei Korhazak &amp; Egyetemi Oktatokorhaz /ID# 208184</name>
      <address>
        <city>Nyíregyháza</city>
        <state>Szabolcs-Szatmar-Bereg</state>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revita Reumatologiai Rendelo /ID# 208187</name>
      <address>
        <city>Budapest</city>
        <zip>1027</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMED Rehabilitacios es Diagnosztikai Kozpont /ID# 208188</name>
      <address>
        <city>Szekesfehervar</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vital Medical Center Orvosi-es Fogaszati Kozpont /ID# 208185</name>
      <address>
        <city>Veszprem</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malopolskie Centrum Kliniczne /ID# 209902</name>
      <address>
        <city>Cracow</city>
        <state>Malopolskie</state>
        <zip>30-149</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McBk Sc /Id# 212577</name>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <state>Mazowieckie</state>
        <zip>05-825</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NBR Polska /ID# 209904</name>
      <address>
        <city>Warsaw</city>
        <state>Mazowieckie</state>
        <zip>00-465</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinicMed Daniluk, Nowak Sp.j. /ID# 212578</name>
      <address>
        <city>Białystok</city>
        <state>Podlaskie</state>
        <zip>15-879</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reumatika - Centrum Reumatologii NZOZ /ID# 209903</name>
      <address>
        <city>Warsaw</city>
        <zip>02-691</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario A Coruña - CHUAC /ID# 207732</name>
      <address>
        <city>A Coruña</city>
        <state>A Coruna</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Unversitario Marques de Valdecilla /ID# 207729</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional de Malaga /ID# 207735</name>
      <address>
        <city>Málaga</city>
        <state>Malaga</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic /ID# 207740</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Basurto /ID# 207737</name>
      <address>
        <city>Bilbao</city>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves /ID# 209975</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario San Carlos /ID# 207738</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politecnico La Fe /ID# 207739</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oxford /ID# 210571</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.rxabbvie.com/</url>
    <description>Related Info.</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 8, 2019</study_first_submitted>
  <study_first_submitted_qc>January 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2019</study_first_posted>
  <results_first_submitted>August 18, 2021</results_first_submitted>
  <results_first_submitted_qc>August 18, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 16, 2021</results_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Elsubrutinib</keyword>
  <keyword>ABBV-105</keyword>
  <keyword>Upadacitinib</keyword>
  <keyword>ABBV-599</keyword>
  <keyword>Rheumatoid Arthritis (RA)</keyword>
  <keyword>Long-term extension (LTE)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Upadacitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 6, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT03823378/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 10, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT03823378/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>All randomized participants</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ABBV-599 in M16-063/ABBV-599 in M16-763</title>
          <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks</description>
        </group>
        <group group_id="P2">
          <title>ABBV-105 60 mg/UPA Placebo</title>
          <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
        </group>
        <group group_id="P3">
          <title>ABBV-105 20 mg/UPA Placebo</title>
          <description>20 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
        </group>
        <group group_id="P4">
          <title>ABBV-105 5 mg/UPA Placebo</title>
          <description>5 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
        </group>
        <group group_id="P5">
          <title>UPA 15 mg/ABBV-105 Placebo</title>
          <description>15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks; placebo capsule for elsubrutinib once a day by mouth for 48 weeks</description>
        </group>
        <group group_id="P6">
          <title>Placebo in M16-063/ABBV-599 in M16-763</title>
          <description>Placebo in M16-063; 60 mg elsubrutinib capsule once a day by mouth for 48 weeks and 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks in M16-763</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="20"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="18"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other, not specified</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="17"/>
                <participants group_id="P6" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set: all participants who completed Study M16-063 and received at least 1 dose of assigned study drug in Study M16-763</population>
      <group_list>
        <group group_id="B1">
          <title>ABBV-599 in M16-063/ABBV-599 in M16-763</title>
          <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks</description>
        </group>
        <group group_id="B2">
          <title>ABBV-105 60 mg/UPA Placebo</title>
          <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
        </group>
        <group group_id="B3">
          <title>ABBV-105 20 mg/UPA Placebo</title>
          <description>20 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
        </group>
        <group group_id="B4">
          <title>ABBV-105 5 mg/UPA Placebo</title>
          <description>5 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
        </group>
        <group group_id="B5">
          <title>UPA 15 mg/ABBV-105 Placebo</title>
          <description>15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks; placebo capsule for elsubrutinib once a day by mouth for 48 weeks</description>
        </group>
        <group group_id="B6">
          <title>Placebo in M16-063/ABBV-599 in M16-763</title>
          <description>Placebo in M16-063; 60 mg elsubrutinib capsule once a day by mouth for 48 weeks and 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks in M16-763</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="20"/>
            <count group_id="B6" value="9"/>
            <count group_id="B7" value="97"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.5" spread="12.64"/>
                    <measurement group_id="B2" value="58.6" spread="8.75"/>
                    <measurement group_id="B3" value="58.5" spread="12.07"/>
                    <measurement group_id="B4" value="54.5" spread="12.21"/>
                    <measurement group_id="B5" value="61.7" spread="8.99"/>
                    <measurement group_id="B6" value="59.4" spread="9.48"/>
                    <measurement group_id="B7" value="58.5" spread="10.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Rheumatoid Arthritis Diagnosis</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.024" spread="5.6087"/>
                    <measurement group_id="B2" value="14.212" spread="9.0327"/>
                    <measurement group_id="B3" value="5.435" spread="3.2458"/>
                    <measurement group_id="B4" value="9.466" spread="6.6508"/>
                    <measurement group_id="B5" value="13.571" spread="7.8086"/>
                    <measurement group_id="B6" value="9.684" spread="5.6087"/>
                    <measurement group_id="B7" value="10.778" spread="7.0861"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events (AEs)</title>
        <description>An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug as either having a reasonable possibility or no reasonable possibility. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug.</description>
        <time_frame>On or after the first dose of study drug in Study M16-763, and up to 30 days after the last dose of study drug in Study M16-763, up to 52 weeks</time_frame>
        <population>Safety Analysis Set: all participants who completed Study M16-063 and received at least 1 dose of assigned study drug in Study M16-763</population>
        <group_list>
          <group group_id="O1">
            <title>ABBV-599 in M16-063/ABBV-599 in M16-763</title>
            <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>ABBV-105 60 mg/UPA Placebo</title>
            <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O3">
            <title>ABBV-105 20 mg/UPA Placebo</title>
            <description>20 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O4">
            <title>ABBV-105 5 mg/UPA Placebo</title>
            <description>5 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O5">
            <title>UPA 15 mg/ABBV-105 Placebo</title>
            <description>15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks; placebo capsule for elsubrutinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O6">
            <title>Placebo in M16-063/ABBV-599 in M16-763</title>
            <description>Placebo in M16-063; 60 mg elsubrutinib capsule once a day by mouth for 48 weeks and 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks in M16-763</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs)</title>
          <description>An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug as either having a reasonable possibility or no reasonable possibility. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug.</description>
          <population>Safety Analysis Set: all participants who completed Study M16-063 and received at least 1 dose of assigned study drug in Study M16-763</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Disease Activity Score 28 C-reactive Protein (DAS28-CRP) From Baseline of Study M16-063 at Each Study Visit in Study M16-763</title>
        <description>The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from Baseline indicates improvement in disease activity.</description>
        <time_frame>Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763</time_frame>
        <population>Full Analysis Set: all participants who completed Study M16-063 and received at least 1 dose of assigned study drug in Study M16-763 with available data</population>
        <group_list>
          <group group_id="O1">
            <title>ABBV-599 in M16-063/ABBV-599 in M16-763</title>
            <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>ABBV-105 60 mg/UPA Placebo</title>
            <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O3">
            <title>ABBV-105 20 mg/UPA Placebo</title>
            <description>20 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O4">
            <title>ABBV-105 5 mg/UPA Placebo</title>
            <description>5 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O5">
            <title>UPA 15 mg/ABBV-105 Placebo</title>
            <description>15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks; placebo capsule for elsubrutinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O6">
            <title>Placebo in M16-063/ABBV-599 in M16-763</title>
            <description>Placebo in M16-063; 60 mg elsubrutinib capsule once a day by mouth for 48 weeks and 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks in M16-763</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Disease Activity Score 28 C-reactive Protein (DAS28-CRP) From Baseline of Study M16-063 at Each Study Visit in Study M16-763</title>
          <description>The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from Baseline indicates improvement in disease activity.</description>
          <population>Full Analysis Set: all participants who completed Study M16-063 and received at least 1 dose of assigned study drug in Study M16-763 with available data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="18"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.27" lower_limit="-3.79" upper_limit="-2.75"/>
                    <measurement group_id="O2" value="-1.98" lower_limit="-2.83" upper_limit="-1.12"/>
                    <measurement group_id="O3" value="-1.93" lower_limit="-3.01" upper_limit="-0.85"/>
                    <measurement group_id="O4" value="-2.55" lower_limit="-3.50" upper_limit="-1.60"/>
                    <measurement group_id="O5" value="-3.88" lower_limit="-4.63" upper_limit="-3.14"/>
                    <measurement group_id="O6" value="-2.87" lower_limit="-4.05" upper_limit="-1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.43" lower_limit="-3.90" upper_limit="-2.95"/>
                    <measurement group_id="O2" value="-2.62" lower_limit="-3.56" upper_limit="-1.68"/>
                    <measurement group_id="O3" value="-2.02" lower_limit="-3.18" upper_limit="-0.86"/>
                    <measurement group_id="O4" value="-3.20" lower_limit="-4.10" upper_limit="-2.30"/>
                    <measurement group_id="O5" value="-4.02" lower_limit="-4.62" upper_limit="-3.43"/>
                    <measurement group_id="O6" value="-3.61" lower_limit="-4.94" upper_limit="-2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.17" lower_limit="-3.86" upper_limit="-2.47"/>
                    <measurement group_id="O2" value="-2.37" lower_limit="-3.71" upper_limit="-1.03"/>
                    <measurement group_id="O3" value="-1.45" lower_limit="-2.30" upper_limit="-0.60"/>
                    <measurement group_id="O4" value="-3.30" lower_limit="-4.43" upper_limit="-2.17"/>
                    <measurement group_id="O5" value="-3.84" lower_limit="-4.56" upper_limit="-3.12"/>
                    <measurement group_id="O6" value="-4.08" lower_limit="-4.73" upper_limit="-3.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.45" lower_limit="-4.14" upper_limit="-2.77"/>
                    <measurement group_id="O2" value="-3.12" lower_limit="-3.99" upper_limit="-2.25"/>
                    <measurement group_id="O3" value="-1.63" lower_limit="-2.37" upper_limit="-0.89"/>
                    <measurement group_id="O4" value="-3.00" lower_limit="-4.17" upper_limit="-1.83"/>
                    <measurement group_id="O5" value="-4.15" lower_limit="-5.02" upper_limit="-3.29"/>
                    <measurement group_id="O6" value="-3.77" lower_limit="-4.79" upper_limit="-2.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.55" lower_limit="-4.32" upper_limit="-2.78"/>
                    <measurement group_id="O2" value="-2.77" lower_limit="-4.92" upper_limit="-0.62"/>
                    <measurement group_id="O3" value="-1.68" lower_limit="-3.10" upper_limit="-0.27"/>
                    <measurement group_id="O4" value="-3.16" lower_limit="-4.49" upper_limit="-1.84"/>
                    <measurement group_id="O5" value="-4.38" lower_limit="-5.67" upper_limit="-3.09"/>
                    <measurement group_id="O6" value="-3.86" lower_limit="-4.88" upper_limit="-2.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.06" lower_limit="-4.88" upper_limit="-3.25"/>
                    <measurement group_id="O2" value="-3.21" lower_limit="-22.18" upper_limit="15.75"/>
                    <measurement group_id="O3" value="-2.55" lower_limit="-6.90" upper_limit="1.79"/>
                    <measurement group_id="O4" value="-3.41" lower_limit="-4.92" upper_limit="-1.89"/>
                    <measurement group_id="O5" value="-4.12" lower_limit="-5.43" upper_limit="-2.81"/>
                    <measurement group_id="O6" value="-3.69" lower_limit="-5.19" upper_limit="-2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Low Disease Activity (LDA) Based on Disease Activity Score 28 C-reactive Protein (DAS28-CRP)</title>
        <description>The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. Low Disease Activity (LDA) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) of less than or equal to 3.2.</description>
        <time_frame>Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763</time_frame>
        <population>Full Analysis Set: all participants who completed Study M16-063 and received at least 1 dose of assigned study drug in Study M16-763 with available data</population>
        <group_list>
          <group group_id="O1">
            <title>ABBV-599 in M16-063/ABBV-599 in M16-763</title>
            <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>ABBV-105 60 mg/UPA Placebo</title>
            <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O3">
            <title>ABBV-105 20 mg/UPA Placebo</title>
            <description>20 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O4">
            <title>ABBV-105 5 mg/UPA Placebo</title>
            <description>5 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O5">
            <title>UPA 15 mg/ABBV-105 Placebo</title>
            <description>15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks; placebo capsule for elsubrutinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O6">
            <title>Placebo in M16-063/ABBV-599 in M16-763</title>
            <description>Placebo in M16-063; 60 mg elsubrutinib capsule once a day by mouth for 48 weeks and 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks in M16-763</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Low Disease Activity (LDA) Based on Disease Activity Score 28 C-reactive Protein (DAS28-CRP)</title>
          <description>The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. Low Disease Activity (LDA) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) of less than or equal to 3.2.</description>
          <population>Full Analysis Set: all participants who completed Study M16-063 and received at least 1 dose of assigned study drug in Study M16-763 with available data</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="18"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.3" lower_limit="58.10" upper_limit="90.34"/>
                    <measurement group_id="O2" value="26.7" lower_limit="10.90" upper_limit="51.95"/>
                    <measurement group_id="O3" value="44.4" lower_limit="18.88" upper_limit="73.33"/>
                    <measurement group_id="O4" value="20.0" lower_limit="5.67" upper_limit="50.98"/>
                    <measurement group_id="O5" value="77.8" lower_limit="54.79" upper_limit="91.00"/>
                    <measurement group_id="O6" value="62.5" lower_limit="30.57" upper_limit="86.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8" lower_limit="59.24" upper_limit="89.39"/>
                    <measurement group_id="O2" value="53.8" lower_limit="29.14" upper_limit="76.79"/>
                    <measurement group_id="O3" value="44.4" lower_limit="18.88" upper_limit="73.33"/>
                    <measurement group_id="O4" value="50.0" lower_limit="23.66" upper_limit="76.34"/>
                    <measurement group_id="O5" value="88.2" lower_limit="65.66" upper_limit="96.71"/>
                    <measurement group_id="O6" value="85.7" lower_limit="48.69" upper_limit="97.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.3" lower_limit="58.10" upper_limit="90.34"/>
                    <measurement group_id="O2" value="76.9" lower_limit="49.74" upper_limit="91.82"/>
                    <measurement group_id="O3" value="28.6" lower_limit="8.22" upper_limit="64.11"/>
                    <measurement group_id="O4" value="60.0" lower_limit="31.27" upper_limit="83.18"/>
                    <measurement group_id="O5" value="87.5" lower_limit="63.98" upper_limit="96.50"/>
                    <measurement group_id="O6" value="100" lower_limit="67.56" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5" lower_limit="69.00" upper_limit="95.66"/>
                    <measurement group_id="O2" value="87.5" lower_limit="52.91" upper_limit="97.76"/>
                    <measurement group_id="O3" value="25.0" lower_limit="4.56" upper_limit="69.94"/>
                    <measurement group_id="O4" value="40.0" lower_limit="16.82" upper_limit="68.73"/>
                    <measurement group_id="O5" value="91.7" lower_limit="64.61" upper_limit="98.51"/>
                    <measurement group_id="O6" value="100" lower_limit="60.97" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8" lower_limit="54.79" upper_limit="91.00"/>
                    <measurement group_id="O2" value="66.7" lower_limit="30.00" upper_limit="90.32"/>
                    <measurement group_id="O3" value="50.0" lower_limit="15.00" upper_limit="85.00"/>
                    <measurement group_id="O4" value="37.5" lower_limit="13.68" upper_limit="69.43"/>
                    <measurement group_id="O5" value="87.5" lower_limit="52.91" upper_limit="97.76"/>
                    <measurement group_id="O6" value="100" lower_limit="60.97" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="70.09" upper_limit="100.00"/>
                    <measurement group_id="O2" value="50.0" lower_limit="9.45" upper_limit="90.55"/>
                    <measurement group_id="O3" value="100" lower_limit="34.24" upper_limit="100.00"/>
                    <measurement group_id="O4" value="60.0" lower_limit="23.07" upper_limit="88.24"/>
                    <measurement group_id="O5" value="100" lower_limit="56.55" upper_limit="100.00"/>
                    <measurement group_id="O6" value="75.0" lower_limit="30.06" upper_limit="95.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Clinical Remission (CR) Based on Disease Activity Score 28 C-reactive Protein (DAS28-CRP)</title>
        <description>The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. Clinical Remission (CR) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) of less than 2.6.</description>
        <time_frame>Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763</time_frame>
        <population>Full Analysis Set: all participants who completed Study M16-063 and received at least 1 dose of assigned study drug in Study M16-763 with available data</population>
        <group_list>
          <group group_id="O1">
            <title>ABBV-599 in M16-063/ABBV-599 in M16-763</title>
            <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>ABBV-105 60 mg/UPA Placebo</title>
            <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O3">
            <title>ABBV-105 20 mg/UPA Placebo</title>
            <description>20 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O4">
            <title>ABBV-105 5 mg/UPA Placebo</title>
            <description>5 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O5">
            <title>UPA 15 mg/ABBV-105 Placebo</title>
            <description>15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks; placebo capsule for elsubrutinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O6">
            <title>Placebo in M16-063/ABBV-599 in M16-763</title>
            <description>Placebo in M16-063; 60 mg elsubrutinib capsule once a day by mouth for 48 weeks and 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks in M16-763</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Clinical Remission (CR) Based on Disease Activity Score 28 C-reactive Protein (DAS28-CRP)</title>
          <description>The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. Clinical Remission (CR) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) of less than 2.6.</description>
          <population>Full Analysis Set: all participants who completed Study M16-063 and received at least 1 dose of assigned study drug in Study M16-763 with available data</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="18"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.5" lower_limit="36.81" upper_limit="74.37"/>
                    <measurement group_id="O2" value="20.0" lower_limit="7.05" upper_limit="45.19"/>
                    <measurement group_id="O3" value="11.1" lower_limit="1.99" upper_limit="43.50"/>
                    <measurement group_id="O4" value="20.0" lower_limit="5.67" upper_limit="50.98"/>
                    <measurement group_id="O5" value="77.8" lower_limit="54.79" upper_limit="91.00"/>
                    <measurement group_id="O6" value="50.0" lower_limit="21.52" upper_limit="78.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.4" lower_limit="51.52" upper_limit="84.15"/>
                    <measurement group_id="O2" value="53.8" lower_limit="29.14" upper_limit="76.79"/>
                    <measurement group_id="O3" value="33.3" lower_limit="12.06" upper_limit="64.58"/>
                    <measurement group_id="O4" value="30.0" lower_limit="10.78" upper_limit="60.32"/>
                    <measurement group_id="O5" value="70.6" lower_limit="46.87" upper_limit="86.72"/>
                    <measurement group_id="O6" value="71.4" lower_limit="35.89" upper_limit="91.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.2" lower_limit="44.89" upper_limit="81.19"/>
                    <measurement group_id="O2" value="46.2" lower_limit="23.21" upper_limit="70.86"/>
                    <measurement group_id="O3" value="0" lower_limit="0.00" upper_limit="35.43"/>
                    <measurement group_id="O4" value="40.0" lower_limit="16.82" upper_limit="68.73"/>
                    <measurement group_id="O5" value="87.5" lower_limit="63.98" upper_limit="96.50"/>
                    <measurement group_id="O6" value="100" lower_limit="67.56" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" lower_limit="46.71" upper_limit="82.03"/>
                    <measurement group_id="O2" value="62.5" lower_limit="30.57" upper_limit="86.32"/>
                    <measurement group_id="O3" value="0" lower_limit="0.00" upper_limit="48.99"/>
                    <measurement group_id="O4" value="20.0" lower_limit="5.67" upper_limit="50.98"/>
                    <measurement group_id="O5" value="75.0" lower_limit="46.77" upper_limit="91.11"/>
                    <measurement group_id="O6" value="66.7" lower_limit="30.00" upper_limit="90.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2" lower_limit="49.13" upper_limit="87.50"/>
                    <measurement group_id="O2" value="66.7" lower_limit="30.00" upper_limit="90.32"/>
                    <measurement group_id="O3" value="0" lower_limit="0.00" upper_limit="48.99"/>
                    <measurement group_id="O4" value="25.0" lower_limit="7.15" upper_limit="59.07"/>
                    <measurement group_id="O5" value="62.5" lower_limit="30.57" upper_limit="86.32"/>
                    <measurement group_id="O6" value="83.3" lower_limit="43.65" upper_limit="96.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8" lower_limit="45.26" upper_limit="93.68"/>
                    <measurement group_id="O2" value="50.0" lower_limit="9.45" upper_limit="90.55"/>
                    <measurement group_id="O3" value="50.0" lower_limit="9.45" upper_limit="90.55"/>
                    <measurement group_id="O4" value="0" lower_limit="0.00" upper_limit="43.45"/>
                    <measurement group_id="O5" value="60.0" lower_limit="23.07" upper_limit="88.24"/>
                    <measurement group_id="O6" value="75.0" lower_limit="30.06" upper_limit="95.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Clinical Disease Activity Index (CDAI) From Baseline of Study M16-063</title>
        <description>The CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. A negative change from Baseline indicates improvement in disease activity.</description>
        <time_frame>Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763</time_frame>
        <population>Full Analysis Set: all participants who completed Study M16-063 and received at least 1 dose of assigned study drug in Study M16-763 with available data</population>
        <group_list>
          <group group_id="O1">
            <title>ABBV-599 in M16-063/ABBV-599 in M16-763</title>
            <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>ABBV-105 60 mg/UPA Placebo</title>
            <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O3">
            <title>ABBV-105 20 mg/UPA Placebo</title>
            <description>20 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O4">
            <title>ABBV-105 5 mg/UPA Placebo</title>
            <description>5 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O5">
            <title>UPA 15 mg/ABBV-105 Placebo</title>
            <description>15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks; placebo capsule for elsubrutinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O6">
            <title>Placebo in M16-063/ABBV-599 in M16-763</title>
            <description>Placebo in M16-063; 60 mg elsubrutinib capsule once a day by mouth for 48 weeks and 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks in M16-763</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Clinical Disease Activity Index (CDAI) From Baseline of Study M16-063</title>
          <description>The CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. A negative change from Baseline indicates improvement in disease activity.</description>
          <population>Full Analysis Set: all participants who completed Study M16-063 and received at least 1 dose of assigned study drug in Study M16-763 with available data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="17"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.68" lower_limit="-40.72" upper_limit="-26.64"/>
                    <measurement group_id="O2" value="-23.77" lower_limit="-32.65" upper_limit="-14.90"/>
                    <measurement group_id="O3" value="-19.16" lower_limit="-28.05" upper_limit="-10.26"/>
                    <measurement group_id="O4" value="-27.00" lower_limit="-42.89" upper_limit="-11.11"/>
                    <measurement group_id="O5" value="-36.01" lower_limit="-44.11" upper_limit="-27.91"/>
                    <measurement group_id="O6" value="-28.65" lower_limit="-37.00" upper_limit="-20.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.47" lower_limit="-39.66" upper_limit="-27.27"/>
                    <measurement group_id="O2" value="-27.20" lower_limit="-34.18" upper_limit="-20.22"/>
                    <measurement group_id="O3" value="-19.84" lower_limit="-30.65" upper_limit="-9.03"/>
                    <measurement group_id="O4" value="-35.59" lower_limit="-45.25" upper_limit="-25.93"/>
                    <measurement group_id="O5" value="-38.27" lower_limit="-45.66" upper_limit="-30.88"/>
                    <measurement group_id="O6" value="-32.93" lower_limit="-41.70" upper_limit="-24.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.07" lower_limit="-40.11" upper_limit="-24.03"/>
                    <measurement group_id="O2" value="-22.40" lower_limit="-34.25" upper_limit="-10.55"/>
                    <measurement group_id="O3" value="-16.72" lower_limit="-22.28" upper_limit="-11.16"/>
                    <measurement group_id="O4" value="-35.92" lower_limit="-46.64" upper_limit="-25.20"/>
                    <measurement group_id="O5" value="-36.86" lower_limit="-46.20" upper_limit="-27.52"/>
                    <measurement group_id="O6" value="-34.00" lower_limit="-42.21" upper_limit="-25.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.28" lower_limit="-43.23" upper_limit="-27.33"/>
                    <measurement group_id="O2" value="-28.86" lower_limit="-36.56" upper_limit="-21.16"/>
                    <measurement group_id="O3" value="-19.17" lower_limit="-32.10" upper_limit="-6.23"/>
                    <measurement group_id="O4" value="-33.99" lower_limit="-47.10" upper_limit="-20.88"/>
                    <measurement group_id="O5" value="-42.20" lower_limit="-52.14" upper_limit="-32.26"/>
                    <measurement group_id="O6" value="-32.92" lower_limit="-41.43" upper_limit="-24.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.26" lower_limit="-45.44" upper_limit="-27.08"/>
                    <measurement group_id="O2" value="-22.58" lower_limit="-41.15" upper_limit="-4.02"/>
                    <measurement group_id="O3" value="-18.87" lower_limit="-36.40" upper_limit="-1.33"/>
                    <measurement group_id="O4" value="-34.77" lower_limit="-49.11" upper_limit="-20.44"/>
                    <measurement group_id="O5" value="-45.69" lower_limit="-57.45" upper_limit="-33.93"/>
                    <measurement group_id="O6" value="-35.72" lower_limit="-45.75" upper_limit="-25.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.99" lower_limit="-49.56" upper_limit="-26.41"/>
                    <measurement group_id="O2" value="-29.70" lower_limit="-216.48" upper_limit="157.08"/>
                    <measurement group_id="O3" value="-24.95" lower_limit="-78.95" upper_limit="29.05"/>
                    <measurement group_id="O4" value="-37.20" lower_limit="-56.11" upper_limit="-18.29"/>
                    <measurement group_id="O5" value="-43.98" lower_limit="-58.77" upper_limit="-29.19"/>
                    <measurement group_id="O6" value="-34.38" lower_limit="-46.14" upper_limit="-22.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Low Disease Activity (LDA) Based on Clinical Disease Activity Index (CDAI) Criteria</title>
        <description>The CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. Low Disease Activity (LDA) based on CDAI is defined as achieving a total CDAI score of less than or equal to 10.</description>
        <time_frame>Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763</time_frame>
        <population>Full Analysis Set: all participants who completed Study M16-063 and received at least 1 dose of assigned study drug in Study M16-763 with available data</population>
        <group_list>
          <group group_id="O1">
            <title>ABBV-599 in M16-063/ABBV-599 in M16-763</title>
            <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>ABBV-105 60 mg/UPA Placebo</title>
            <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O3">
            <title>ABBV-105 20 mg/UPA Placebo</title>
            <description>20 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O4">
            <title>ABBV-105 5 mg/UPA Placebo</title>
            <description>5 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O5">
            <title>UPA 15 mg/ABBV-105 Placebo</title>
            <description>15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks; placebo capsule for elsubrutinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O6">
            <title>Placebo in M16-063/ABBV-599 in M16-763</title>
            <description>Placebo in M16-063; 60 mg elsubrutinib capsule once a day by mouth for 48 weeks and 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks in M16-763</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Low Disease Activity (LDA) Based on Clinical Disease Activity Index (CDAI) Criteria</title>
          <description>The CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. Low Disease Activity (LDA) based on CDAI is defined as achieving a total CDAI score of less than or equal to 10.</description>
          <population>Full Analysis Set: all participants who completed Study M16-063 and received at least 1 dose of assigned study drug in Study M16-763 with available data</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="18"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.6" lower_limit="62.86" upper_limit="93.02"/>
                    <measurement group_id="O2" value="40.0" lower_limit="19.82" upper_limit="64.25"/>
                    <measurement group_id="O3" value="44.4" lower_limit="18.88" upper_limit="73.33"/>
                    <measurement group_id="O4" value="50.0" lower_limit="21.52" upper_limit="78.48"/>
                    <measurement group_id="O5" value="77.8" lower_limit="54.79" upper_limit="91.00"/>
                    <measurement group_id="O6" value="62.5" lower_limit="30.57" upper_limit="86.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9" lower_limit="71.94" upper_limit="96.15"/>
                    <measurement group_id="O2" value="69.2" lower_limit="42.37" upper_limit="87.32"/>
                    <measurement group_id="O3" value="55.6" lower_limit="26.67" upper_limit="81.12"/>
                    <measurement group_id="O4" value="80.0" lower_limit="49.02" upper_limit="94.33"/>
                    <measurement group_id="O5" value="88.2" lower_limit="65.66" upper_limit="96.71"/>
                    <measurement group_id="O6" value="100" lower_limit="67.56" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.3" lower_limit="58.10" upper_limit="90.34"/>
                    <measurement group_id="O2" value="76.9" lower_limit="49.74" upper_limit="91.82"/>
                    <measurement group_id="O3" value="42.9" lower_limit="15.82" upper_limit="74.95"/>
                    <measurement group_id="O4" value="80.0" lower_limit="49.02" upper_limit="94.33"/>
                    <measurement group_id="O5" value="81.3" lower_limit="56.99" upper_limit="93.41"/>
                    <measurement group_id="O6" value="100" lower_limit="67.56" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.4" lower_limit="66.67" upper_limit="95.25"/>
                    <measurement group_id="O2" value="87.5" lower_limit="52.91" upper_limit="97.76"/>
                    <measurement group_id="O3" value="75.0" lower_limit="30.06" upper_limit="95.44"/>
                    <measurement group_id="O4" value="70.0" lower_limit="39.68" upper_limit="89.22"/>
                    <measurement group_id="O5" value="83.3" lower_limit="55.20" upper_limit="95.30"/>
                    <measurement group_id="O6" value="100" lower_limit="60.97" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8" lower_limit="54.79" upper_limit="91.00"/>
                    <measurement group_id="O2" value="66.7" lower_limit="30.00" upper_limit="90.32"/>
                    <measurement group_id="O3" value="75.0" lower_limit="30.06" upper_limit="95.44"/>
                    <measurement group_id="O4" value="62.5" lower_limit="30.57" upper_limit="86.32"/>
                    <measurement group_id="O5" value="87.5" lower_limit="52.91" upper_limit="97.76"/>
                    <measurement group_id="O6" value="100" lower_limit="56.55" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="70.09" upper_limit="100.00"/>
                    <measurement group_id="O2" value="50.0" lower_limit="9.45" upper_limit="90.55"/>
                    <measurement group_id="O3" value="100" lower_limit="34.24" upper_limit="100.00"/>
                    <measurement group_id="O4" value="80.0" lower_limit="37.55" upper_limit="96.38"/>
                    <measurement group_id="O5" value="80.0" lower_limit="37.55" upper_limit="96.38"/>
                    <measurement group_id="O6" value="75.0" lower_limit="30.06" upper_limit="95.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Clinical Remission (CR) Based on Clinical Disease Activity Index (CDAI) Criteria</title>
        <description>The CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. Complete Remission (CR) based on CDAI is defined as achieving a total CDAI score of less than or equal to 2.8.</description>
        <time_frame>Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763</time_frame>
        <population>Full Analysis Set: all participants who completed Study M16-063 and received at least 1 dose of assigned study drug in Study M16-763 with available data</population>
        <group_list>
          <group group_id="O1">
            <title>ABBV-599 in M16-063/ABBV-599 in M16-763</title>
            <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>ABBV-105 60 mg/UPA Placebo</title>
            <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O3">
            <title>ABBV-105 20 mg/UPA Placebo</title>
            <description>20 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O4">
            <title>ABBV-105 5 mg/UPA Placebo</title>
            <description>5 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O5">
            <title>UPA 15 mg/ABBV-105 Placebo</title>
            <description>15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks; placebo capsule for elsubrutinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O6">
            <title>Placebo in M16-063/ABBV-599 in M16-763</title>
            <description>Placebo in M16-063; 60 mg elsubrutinib capsule once a day by mouth for 48 weeks and 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks in M16-763</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Clinical Remission (CR) Based on Clinical Disease Activity Index (CDAI) Criteria</title>
          <description>The CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. Complete Remission (CR) based on CDAI is defined as achieving a total CDAI score of less than or equal to 2.8.</description>
          <population>Full Analysis Set: all participants who completed Study M16-063 and received at least 1 dose of assigned study drug in Study M16-763 with available data</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="18"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" lower_limit="6.98" upper_limit="37.14"/>
                    <measurement group_id="O2" value="13.3" lower_limit="3.74" upper_limit="37.88"/>
                    <measurement group_id="O3" value="11.1" lower_limit="1.99" upper_limit="43.50"/>
                    <measurement group_id="O4" value="12.5" lower_limit="2.24" upper_limit="47.09"/>
                    <measurement group_id="O5" value="55.6" lower_limit="33.72" upper_limit="75.44"/>
                    <measurement group_id="O6" value="25.0" lower_limit="7.15" upper_limit="59.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.6" lower_limit="15.85" upper_limit="48.48"/>
                    <measurement group_id="O2" value="23.1" lower_limit="8.18" upper_limit="50.26"/>
                    <measurement group_id="O3" value="11.1" lower_limit="1.99" upper_limit="43.50"/>
                    <measurement group_id="O4" value="10.0" lower_limit="1.79" upper_limit="40.42"/>
                    <measurement group_id="O5" value="58.8" lower_limit="36.01" upper_limit="78.39"/>
                    <measurement group_id="O6" value="50.0" lower_limit="21.52" upper_limit="78.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1" lower_limit="12.55" upper_limit="46.47"/>
                    <measurement group_id="O2" value="30.8" lower_limit="12.68" upper_limit="57.63"/>
                    <measurement group_id="O3" value="14.3" lower_limit="2.57" upper_limit="51.31"/>
                    <measurement group_id="O4" value="30.0" lower_limit="10.78" upper_limit="60.32"/>
                    <measurement group_id="O5" value="43.8" lower_limit="23.10" upper_limit="66.82"/>
                    <measurement group_id="O6" value="87.5" lower_limit="52.91" upper_limit="97.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" lower_limit="19.73" upper_limit="57.05"/>
                    <measurement group_id="O2" value="25.0" lower_limit="7.15" upper_limit="59.07"/>
                    <measurement group_id="O3" value="25.0" lower_limit="4.56" upper_limit="69.94"/>
                    <measurement group_id="O4" value="10.0" lower_limit="1.79" upper_limit="40.42"/>
                    <measurement group_id="O5" value="41.7" lower_limit="19.33" upper_limit="68.05"/>
                    <measurement group_id="O6" value="50.0" lower_limit="18.76" upper_limit="81.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4" lower_limit="24.56" upper_limit="66.28"/>
                    <measurement group_id="O2" value="33.3" lower_limit="9.68" upper_limit="70.00"/>
                    <measurement group_id="O3" value="0" lower_limit="0.00" upper_limit="48.99"/>
                    <measurement group_id="O4" value="12.5" lower_limit="2.24" upper_limit="47.09"/>
                    <measurement group_id="O5" value="50.0" lower_limit="21.52" upper_limit="78.48"/>
                    <measurement group_id="O6" value="100" lower_limit="56.55" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="12.06" upper_limit="64.58"/>
                    <measurement group_id="O2" value="50.0" lower_limit="9.45" upper_limit="90.55"/>
                    <measurement group_id="O3" value="50.0" lower_limit="9.45" upper_limit="90.55"/>
                    <measurement group_id="O4" value="20.0" lower_limit="3.62" upper_limit="62.45"/>
                    <measurement group_id="O5" value="60.0" lower_limit="23.07" upper_limit="88.24"/>
                    <measurement group_id="O6" value="50.0" lower_limit="15.00" upper_limit="85.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response</title>
        <description>Participants who met the following 3 conditions for improvement from baseline of Study M16-063 were classified as meeting the American College of Rheumatology 20% response (ACR20) criteria:&#xD;
≥ 20% improvement in 68-tender joint count from Baseline of Study M16-063&#xD;
≥ 20% improvement in 66-swollen joint count from Baseline of Study M16-063 and&#xD;
≥ 20% improvement in at least 3 of the 5 following parameters from Baseline of Study M16-063:&#xD;
Patient's Assessment of Pain (Visual Analog Scale [VAS])&#xD;
Patient's Global Assessment of Disease Activity (PtGA)&#xD;
Physician's Global Assessment of Disease Activity (PhGA)&#xD;
Health Assessment Questionnaire Disability Index (HAQ-DI)&#xD;
High-sensitivity C-reactive protein (hsCRP)</description>
        <time_frame>Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763</time_frame>
        <population>Full Analysis Set: all participants who completed Study M16-063 and received at least 1 dose of assigned study drug in Study M16-763 with available data</population>
        <group_list>
          <group group_id="O1">
            <title>ABBV-599 in M16-063/ABBV-599 in M16-763</title>
            <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>ABBV-105 60 mg/UPA Placebo</title>
            <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O3">
            <title>ABBV-105 20 mg/UPA Placebo</title>
            <description>20 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O4">
            <title>ABBV-105 5 mg/UPA Placebo</title>
            <description>5 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O5">
            <title>UPA 15 mg/ABBV-105 Placebo</title>
            <description>15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks; placebo capsule for elsubrutinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O6">
            <title>Placebo in M16-063/ABBV-599 in M16-763</title>
            <description>Placebo in M16-063; 60 mg elsubrutinib capsule once a day by mouth for 48 weeks and 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks in M16-763</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response</title>
          <description>Participants who met the following 3 conditions for improvement from baseline of Study M16-063 were classified as meeting the American College of Rheumatology 20% response (ACR20) criteria:&#xD;
≥ 20% improvement in 68-tender joint count from Baseline of Study M16-063&#xD;
≥ 20% improvement in 66-swollen joint count from Baseline of Study M16-063 and&#xD;
≥ 20% improvement in at least 3 of the 5 following parameters from Baseline of Study M16-063:&#xD;
Patient's Assessment of Pain (Visual Analog Scale [VAS])&#xD;
Patient's Global Assessment of Disease Activity (PtGA)&#xD;
Physician's Global Assessment of Disease Activity (PhGA)&#xD;
Health Assessment Questionnaire Disability Index (HAQ-DI)&#xD;
High-sensitivity C-reactive protein (hsCRP)</description>
          <population>Full Analysis Set: all participants who completed Study M16-063 and received at least 1 dose of assigned study drug in Study M16-763 with available data</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="17"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9" lower_limit="72.19" upper_limit="97.47"/>
                    <measurement group_id="O2" value="80.0" lower_limit="54.81" upper_limit="92.95"/>
                    <measurement group_id="O3" value="57.1" lower_limit="25.05" upper_limit="84.18"/>
                    <measurement group_id="O4" value="66.7" lower_limit="35.42" upper_limit="87.94"/>
                    <measurement group_id="O5" value="88.2" lower_limit="65.66" upper_limit="96.71"/>
                    <measurement group_id="O6" value="75.0" lower_limit="40.93" upper_limit="92.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.2" lower_limit="81.11" upper_limit="99.32"/>
                    <measurement group_id="O2" value="92.9" lower_limit="68.53" upper_limit="98.73"/>
                    <measurement group_id="O3" value="85.7" lower_limit="48.69" upper_limit="97.43"/>
                    <measurement group_id="O4" value="77.8" lower_limit="45.26" upper_limit="93.68"/>
                    <measurement group_id="O5" value="93.8" lower_limit="71.67" upper_limit="98.89"/>
                    <measurement group_id="O6" value="100" lower_limit="67.56" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.4" lower_limit="66.67" upper_limit="95.25"/>
                    <measurement group_id="O2" value="69.2" lower_limit="42.37" upper_limit="87.32"/>
                    <measurement group_id="O3" value="50.0" lower_limit="18.76" upper_limit="81.24"/>
                    <measurement group_id="O4" value="80.0" lower_limit="49.02" upper_limit="94.33"/>
                    <measurement group_id="O5" value="87.5" lower_limit="63.98" upper_limit="96.50"/>
                    <measurement group_id="O6" value="100" lower_limit="67.56" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.0" lower_limit="67.87" upper_limit="95.46"/>
                    <measurement group_id="O2" value="87.5" lower_limit="52.91" upper_limit="97.76"/>
                    <measurement group_id="O3" value="66.7" lower_limit="20.77" upper_limit="93.85"/>
                    <measurement group_id="O4" value="88.9" lower_limit="56.50" upper_limit="98.01"/>
                    <measurement group_id="O5" value="91.7" lower_limit="64.61" upper_limit="98.51"/>
                    <measurement group_id="O6" value="83.3" lower_limit="43.65" upper_limit="96.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.1" lower_limit="73.02" upper_limit="98.95"/>
                    <measurement group_id="O2" value="83.3" lower_limit="43.65" upper_limit="96.99"/>
                    <measurement group_id="O3" value="66.7" lower_limit="20.77" upper_limit="93.85"/>
                    <measurement group_id="O4" value="85.7" lower_limit="48.69" upper_limit="97.43"/>
                    <measurement group_id="O5" value="87.5" lower_limit="52.91" upper_limit="97.76"/>
                    <measurement group_id="O6" value="100" lower_limit="60.97" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9" lower_limit="56.50" upper_limit="98.01"/>
                    <measurement group_id="O2" value="100" lower_limit="34.24" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100" lower_limit="34.24" upper_limit="100.00"/>
                    <measurement group_id="O4" value="75.0" lower_limit="30.06" upper_limit="95.44"/>
                    <measurement group_id="O5" value="100" lower_limit="56.55" upper_limit="100.00"/>
                    <measurement group_id="O6" value="100" lower_limit="51.01" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response</title>
        <description>Participants who met the following 3 conditions for improvement from baseline of Study M16-063 were classified as meeting the American College of Rheumatology 50% response (ACR50) criteria:&#xD;
≥ 50% improvement in 68-tender joint count from Baseline of Study M16-063&#xD;
≥ 50% improvement in 66-swollen joint count from Baseline of Study M16-063 and&#xD;
≥ 50% improvement in at least 3 of the 5 following parameters from Baseline of Study M16-063:&#xD;
Patient's Assessment of Pain (Visual Analog Scale [VAS])&#xD;
Patient's Global Assessment of Disease Activity (PtGA)&#xD;
Physician's Global Assessment of Disease Activity (PhGA)&#xD;
Health Assessment Questionnaire Disability Index (HAQ-DI)&#xD;
High-sensitivity C-reactive protein (hsCRP)</description>
        <time_frame>Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763</time_frame>
        <population>Full Analysis Set: all participants who completed Study M16-063 and received at least 1 dose of assigned study drug in Study M16-763 with available data</population>
        <group_list>
          <group group_id="O1">
            <title>ABBV-599 in M16-063/ABBV-599 in M16-763</title>
            <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>ABBV-105 60 mg/UPA Placebo</title>
            <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O3">
            <title>ABBV-105 20 mg/UPA Placebo</title>
            <description>20 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O4">
            <title>ABBV-105 5 mg/UPA Placebo</title>
            <description>5 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O5">
            <title>UPA 15 mg/ABBV-105 Placebo</title>
            <description>15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks; placebo capsule for elsubrutinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O6">
            <title>Placebo in M16-063/ABBV-599 in M16-763</title>
            <description>Placebo in M16-063; 60 mg elsubrutinib capsule once a day by mouth for 48 weeks and 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks in M16-763</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response</title>
          <description>Participants who met the following 3 conditions for improvement from baseline of Study M16-063 were classified as meeting the American College of Rheumatology 50% response (ACR50) criteria:&#xD;
≥ 50% improvement in 68-tender joint count from Baseline of Study M16-063&#xD;
≥ 50% improvement in 66-swollen joint count from Baseline of Study M16-063 and&#xD;
≥ 50% improvement in at least 3 of the 5 following parameters from Baseline of Study M16-063:&#xD;
Patient's Assessment of Pain (Visual Analog Scale [VAS])&#xD;
Patient's Global Assessment of Disease Activity (PtGA)&#xD;
Physician's Global Assessment of Disease Activity (PhGA)&#xD;
Health Assessment Questionnaire Disability Index (HAQ-DI)&#xD;
High-sensitivity C-reactive protein (hsCRP)</description>
          <population>Full Analysis Set: all participants who completed Study M16-063 and received at least 1 dose of assigned study drug in Study M16-763 with available data</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="17"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.2" lower_limit="47.32" upper_limit="83.64"/>
                    <measurement group_id="O2" value="46.7" lower_limit="24.81" upper_limit="69.88"/>
                    <measurement group_id="O3" value="40.0" lower_limit="16.82" upper_limit="68.73"/>
                    <measurement group_id="O4" value="40.0" lower_limit="16.82" upper_limit="68.73"/>
                    <measurement group_id="O5" value="70.6" lower_limit="46.87" upper_limit="86.72"/>
                    <measurement group_id="O6" value="62.5" lower_limit="30.57" upper_limit="86.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9" lower_limit="57.95" upper_limit="88.97"/>
                    <measurement group_id="O2" value="64.3" lower_limit="38.76" upper_limit="83.66"/>
                    <measurement group_id="O3" value="42.9" lower_limit="15.82" upper_limit="74.95"/>
                    <measurement group_id="O4" value="66.7" lower_limit="35.42" upper_limit="87.94"/>
                    <measurement group_id="O5" value="87.5" lower_limit="63.98" upper_limit="96.50"/>
                    <measurement group_id="O6" value="100" lower_limit="67.56" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.6" lower_limit="42.95" upper_limit="80.27"/>
                    <measurement group_id="O2" value="61.5" lower_limit="35.52" upper_limit="82.29"/>
                    <measurement group_id="O3" value="16.7" lower_limit="3.01" upper_limit="56.35"/>
                    <measurement group_id="O4" value="60.0" lower_limit="31.27" upper_limit="83.18"/>
                    <measurement group_id="O5" value="87.5" lower_limit="63.98" upper_limit="96.50"/>
                    <measurement group_id="O6" value="100" lower_limit="67.56" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.6" lower_limit="62.86" upper_limit="93.02"/>
                    <measurement group_id="O2" value="62.5" lower_limit="30.57" upper_limit="86.32"/>
                    <measurement group_id="O3" value="33.3" lower_limit="6.15" upper_limit="79.23"/>
                    <measurement group_id="O4" value="66.7" lower_limit="35.42" upper_limit="87.94"/>
                    <measurement group_id="O5" value="75.0" lower_limit="46.77" upper_limit="91.11"/>
                    <measurement group_id="O6" value="66.7" lower_limit="30.00" upper_limit="90.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.4" lower_limit="58.97" upper_limit="93.81"/>
                    <measurement group_id="O2" value="66.7" lower_limit="30.00" upper_limit="90.32"/>
                    <measurement group_id="O3" value="66.7" lower_limit="20.77" upper_limit="93.85"/>
                    <measurement group_id="O4" value="71.4" lower_limit="35.89" upper_limit="91.78"/>
                    <measurement group_id="O5" value="87.5" lower_limit="52.91" upper_limit="97.76"/>
                    <measurement group_id="O6" value="83.3" lower_limit="43.65" upper_limit="96.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9" lower_limit="56.50" upper_limit="98.01"/>
                    <measurement group_id="O2" value="50.0" lower_limit="9.45" upper_limit="90.55"/>
                    <measurement group_id="O3" value="100" lower_limit="34.24" upper_limit="100.00"/>
                    <measurement group_id="O4" value="75.0" lower_limit="30.06" upper_limit="95.44"/>
                    <measurement group_id="O5" value="100" lower_limit="56.55" upper_limit="100.00"/>
                    <measurement group_id="O6" value="100" lower_limit="51.01" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response</title>
        <description>Participants who met the following 3 conditions for improvement from baseline of Study M16-063 were classified as meeting the American College of Rheumatology 70% response (ACR70) criteria:&#xD;
≥ 70% improvement in 68-tender joint count from Baseline of Study M16-063&#xD;
≥ 70% improvement in 66-swollen joint count from Baseline of Study M16-063 and&#xD;
≥ 70% improvement in at least 3 of the 5 following parameters from Baseline of Study M16-063:&#xD;
Patient's Assessment of Pain (Visual Analog Scale [VAS])&#xD;
Patient's Global Assessment of Disease Activity (PtGA)&#xD;
Physician's Global Assessment of Disease Activity (PhGA)&#xD;
Health Assessment Questionnaire Disability Index (HAQ-DI)&#xD;
High-sensitivity C-reactive protein (hsCRP)</description>
        <time_frame>Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763</time_frame>
        <population>Full Analysis Set: all participants who completed Study M16-063 and received at least 1 dose of assigned study drug in Study M16-763 with available data</population>
        <group_list>
          <group group_id="O1">
            <title>ABBV-599 in M16-063/ABBV-599 in M16-763</title>
            <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>ABBV-105 60 mg/UPA Placebo</title>
            <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O3">
            <title>ABBV-105 20 mg/UPA Placebo</title>
            <description>20 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O4">
            <title>ABBV-105 5 mg/UPA Placebo</title>
            <description>5 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O5">
            <title>UPA 15 mg/ABBV-105 Placebo</title>
            <description>15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks; placebo capsule for elsubrutinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O6">
            <title>Placebo in M16-063/ABBV-599 in M16-763</title>
            <description>Placebo in M16-063; 60 mg elsubrutinib capsule once a day by mouth for 48 weeks and 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks in M16-763</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response</title>
          <description>Participants who met the following 3 conditions for improvement from baseline of Study M16-063 were classified as meeting the American College of Rheumatology 70% response (ACR70) criteria:&#xD;
≥ 70% improvement in 68-tender joint count from Baseline of Study M16-063&#xD;
≥ 70% improvement in 66-swollen joint count from Baseline of Study M16-063 and&#xD;
≥ 70% improvement in at least 3 of the 5 following parameters from Baseline of Study M16-063:&#xD;
Patient's Assessment of Pain (Visual Analog Scale [VAS])&#xD;
Patient's Global Assessment of Disease Activity (PtGA)&#xD;
Physician's Global Assessment of Disease Activity (PhGA)&#xD;
Health Assessment Questionnaire Disability Index (HAQ-DI)&#xD;
High-sensitivity C-reactive protein (hsCRP)</description>
          <population>Full Analysis Set: all participants who completed Study M16-063 and received at least 1 dose of assigned study drug in Study M16-763 with available data</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="18"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.8" lower_limit="29.24" upper_limit="67.04"/>
                    <measurement group_id="O2" value="33.3" lower_limit="15.18" upper_limit="58.29"/>
                    <measurement group_id="O3" value="20.0" lower_limit="5.67" upper_limit="50.98"/>
                    <measurement group_id="O4" value="25.0" lower_limit="8.89" upper_limit="53.23"/>
                    <measurement group_id="O5" value="55.6" lower_limit="33.72" upper_limit="75.44"/>
                    <measurement group_id="O6" value="37.5" lower_limit="13.68" upper_limit="69.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.7" lower_limit="38.95" upper_limit="74.46"/>
                    <measurement group_id="O2" value="42.9" lower_limit="21.38" upper_limit="67.41"/>
                    <measurement group_id="O3" value="12.5" lower_limit="2.24" upper_limit="47.09"/>
                    <measurement group_id="O4" value="55.6" lower_limit="26.67" upper_limit="81.12"/>
                    <measurement group_id="O5" value="62.5" lower_limit="38.64" upper_limit="81.52"/>
                    <measurement group_id="O6" value="87.5" lower_limit="52.91" upper_limit="97.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.6" lower_limit="42.95" upper_limit="80.27"/>
                    <measurement group_id="O2" value="46.2" lower_limit="23.21" upper_limit="70.86"/>
                    <measurement group_id="O3" value="14.3" lower_limit="2.57" upper_limit="51.31"/>
                    <measurement group_id="O4" value="60.0" lower_limit="31.27" upper_limit="83.18"/>
                    <measurement group_id="O5" value="68.8" lower_limit="44.40" upper_limit="85.84"/>
                    <measurement group_id="O6" value="87.5" lower_limit="52.91" upper_limit="97.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.3" lower_limit="58.10" upper_limit="90.34"/>
                    <measurement group_id="O2" value="50.0" lower_limit="21.52" upper_limit="78.48"/>
                    <measurement group_id="O3" value="25.0" lower_limit="4.56" upper_limit="69.94"/>
                    <measurement group_id="O4" value="44.4" lower_limit="18.88" upper_limit="73.33"/>
                    <measurement group_id="O5" value="75.0" lower_limit="46.77" upper_limit="91.11"/>
                    <measurement group_id="O6" value="66.7" lower_limit="30.00" upper_limit="90.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.8" lower_limit="36.01" upper_limit="78.39"/>
                    <measurement group_id="O2" value="50.0" lower_limit="18.76" upper_limit="81.24"/>
                    <measurement group_id="O3" value="25.0" lower_limit="4.56" upper_limit="69.94"/>
                    <measurement group_id="O4" value="42.9" lower_limit="15.82" upper_limit="74.95"/>
                    <measurement group_id="O5" value="75.0" lower_limit="40.93" upper_limit="92.85"/>
                    <measurement group_id="O6" value="83.3" lower_limit="43.65" upper_limit="96.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9" lower_limit="56.50" upper_limit="98.01"/>
                    <measurement group_id="O2" value="50.0" lower_limit="9.45" upper_limit="90.55"/>
                    <measurement group_id="O3" value="50.0" lower_limit="9.45" upper_limit="90.55"/>
                    <measurement group_id="O4" value="25.0" lower_limit="4.56" upper_limit="69.94"/>
                    <measurement group_id="O5" value="60.0" lower_limit="23.07" upper_limit="88.24"/>
                    <measurement group_id="O6" value="75.0" lower_limit="30.06" upper_limit="95.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Swollen Joint Count 66 (SJC66) From Baseline of Study M16-063</title>
        <description>Sixty-six joints were assessed for swelling by physical examination. Swelling of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with swelling) to 66 (worst possible score/66 joints with swelling). Negative values indicate improvement from baseline.</description>
        <time_frame>Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763</time_frame>
        <population>Full Analysis Set: all participants who completed Study M16-063 and received at least 1 dose of assigned study drug in Study M16-763 with available data</population>
        <group_list>
          <group group_id="O1">
            <title>ABBV-599 in M16-063/ABBV-599 in M16-763</title>
            <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>ABBV-105 60 mg/UPA Placebo</title>
            <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O3">
            <title>ABBV-105 20 mg/UPA Placebo</title>
            <description>20 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O4">
            <title>ABBV-105 5 mg/UPA Placebo</title>
            <description>5 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O5">
            <title>UPA 15 mg/ABBV-105 Placebo</title>
            <description>15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks; placebo capsule for elsubrutinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O6">
            <title>Placebo in M16-063/ABBV-599 in M16-763</title>
            <description>Placebo in M16-063; 60 mg elsubrutinib capsule once a day by mouth for 48 weeks and 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks in M16-763</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Swollen Joint Count 66 (SJC66) From Baseline of Study M16-063</title>
          <description>Sixty-six joints were assessed for swelling by physical examination. Swelling of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with swelling) to 66 (worst possible score/66 joints with swelling). Negative values indicate improvement from baseline.</description>
          <population>Full Analysis Set: all participants who completed Study M16-063 and received at least 1 dose of assigned study drug in Study M16-763 with available data</population>
          <units>swollen joint counts</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="20"/>
                    <count group_id="O6" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.50" lower_limit="-13.66" upper_limit="-9.34"/>
                    <measurement group_id="O2" value="-9.88" lower_limit="-14.37" upper_limit="-5.38"/>
                    <measurement group_id="O3" value="-8.00" lower_limit="-11.28" upper_limit="-4.72"/>
                    <measurement group_id="O4" value="-13.42" lower_limit="-18.40" upper_limit="-8.43"/>
                    <measurement group_id="O5" value="-12.80" lower_limit="-16.11" upper_limit="-9.49"/>
                    <measurement group_id="O6" value="-9.78" lower_limit="-13.06" upper_limit="-6.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.67" lower_limit="-13.85" upper_limit="-9.49"/>
                    <measurement group_id="O2" value="-10.54" lower_limit="-14.25" upper_limit="-6.82"/>
                    <measurement group_id="O3" value="-7.67" lower_limit="-10.13" upper_limit="-5.21"/>
                    <measurement group_id="O4" value="-15.60" lower_limit="-21.14" upper_limit="-10.06"/>
                    <measurement group_id="O5" value="-13.24" lower_limit="-16.48" upper_limit="-9.99"/>
                    <measurement group_id="O6" value="-10.38" lower_limit="-14.22" upper_limit="-6.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.87" lower_limit="-14.53" upper_limit="-9.21"/>
                    <measurement group_id="O2" value="-7.69" lower_limit="-11.64" upper_limit="-3.74"/>
                    <measurement group_id="O3" value="-5.86" lower_limit="-8.27" upper_limit="-3.44"/>
                    <measurement group_id="O4" value="-15.50" lower_limit="-21.05" upper_limit="-9.95"/>
                    <measurement group_id="O5" value="-13.44" lower_limit="-17.11" upper_limit="-9.77"/>
                    <measurement group_id="O6" value="-10.75" lower_limit="-14.61" upper_limit="-6.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.38" lower_limit="-14.84" upper_limit="-9.91"/>
                    <measurement group_id="O2" value="-10.13" lower_limit="-13.42" upper_limit="-6.83"/>
                    <measurement group_id="O3" value="-7.75" lower_limit="-11.73" upper_limit="-3.77"/>
                    <measurement group_id="O4" value="-14.60" lower_limit="-21.38" upper_limit="-7.82"/>
                    <measurement group_id="O5" value="-14.25" lower_limit="-18.71" upper_limit="-9.79"/>
                    <measurement group_id="O6" value="-10.50" lower_limit="-14.79" upper_limit="-6.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.67" lower_limit="-16.57" upper_limit="-10.77"/>
                    <measurement group_id="O2" value="-8.00" lower_limit="-16.13" upper_limit="0.13"/>
                    <measurement group_id="O3" value="-8.00" lower_limit="-11.90" upper_limit="-4.10"/>
                    <measurement group_id="O4" value="-15.88" lower_limit="-21.34" upper_limit="-10.41"/>
                    <measurement group_id="O5" value="-15.75" lower_limit="-21.84" upper_limit="-9.66"/>
                    <measurement group_id="O6" value="-10.67" lower_limit="-15.34" upper_limit="-5.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.44" lower_limit="-17.73" upper_limit="-11.16"/>
                    <measurement group_id="O2" value="-12.50" lower_limit="-18.85" upper_limit="-6.15"/>
                    <measurement group_id="O3" value="-7.50" lower_limit="-39.27" upper_limit="24.27"/>
                    <measurement group_id="O4" value="-15.40" lower_limit="-23.66" upper_limit="-7.14"/>
                    <measurement group_id="O5" value="-13.00" lower_limit="-20.80" upper_limit="-5.20"/>
                    <measurement group_id="O6" value="-11.25" lower_limit="-16.00" upper_limit="-6.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Tender Joint Count 68 (TJC68) From Baseline of Study M16-063</title>
        <description>Sixty-eight joints were assessed for tenderness by physical examination. Pain or tenderness of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with tenderness) to 68 (worst possible score/68 joints with tenderness). Negative values indicate improvement from baseline.</description>
        <time_frame>Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763</time_frame>
        <population>Full Analysis Set: all participants who completed Study M16-063 and received at least 1 dose of assigned study drug in Study M16-763 with available data</population>
        <group_list>
          <group group_id="O1">
            <title>ABBV-599 in M16-063/ABBV-599 in M16-763</title>
            <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>ABBV-105 60 mg/UPA Placebo</title>
            <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O3">
            <title>ABBV-105 20 mg/UPA Placebo</title>
            <description>20 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O4">
            <title>ABBV-105 5 mg/UPA Placebo</title>
            <description>5 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O5">
            <title>UPA 15 mg/ABBV-105 Placebo</title>
            <description>15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks; placebo capsule for elsubrutinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O6">
            <title>Placebo in M16-063/ABBV-599 in M16-763</title>
            <description>Placebo in M16-063; 60 mg elsubrutinib capsule once a day by mouth for 48 weeks and 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks in M16-763</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Tender Joint Count 68 (TJC68) From Baseline of Study M16-063</title>
          <description>Sixty-eight joints were assessed for tenderness by physical examination. Pain or tenderness of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with tenderness) to 68 (worst possible score/68 joints with tenderness). Negative values indicate improvement from baseline.</description>
          <population>Full Analysis Set: all participants who completed Study M16-063 and received at least 1 dose of assigned study drug in Study M16-763 with available data</population>
          <units>tender joint counts</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="20"/>
                    <count group_id="O6" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.29" lower_limit="-20.95" upper_limit="-13.62"/>
                    <measurement group_id="O2" value="-12.69" lower_limit="-18.77" upper_limit="-6.61"/>
                    <measurement group_id="O3" value="-9.82" lower_limit="-13.63" upper_limit="-6.01"/>
                    <measurement group_id="O4" value="-14.17" lower_limit="-21.70" upper_limit="-6.63"/>
                    <measurement group_id="O5" value="-19.75" lower_limit="-25.63" upper_limit="-13.87"/>
                    <measurement group_id="O6" value="-10.67" lower_limit="-16.21" upper_limit="-5.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.93" lower_limit="-21.84" upper_limit="-14.02"/>
                    <measurement group_id="O2" value="-15.77" lower_limit="-19.37" upper_limit="-12.17"/>
                    <measurement group_id="O3" value="-8.11" lower_limit="-10.95" upper_limit="-5.28"/>
                    <measurement group_id="O4" value="-20.20" lower_limit="-26.97" upper_limit="-13.43"/>
                    <measurement group_id="O5" value="-20.76" lower_limit="-27.39" upper_limit="-14.14"/>
                    <measurement group_id="O6" value="-14.25" lower_limit="-18.44" upper_limit="-10.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.30" lower_limit="-20.32" upper_limit="-12.29"/>
                    <measurement group_id="O2" value="-9.54" lower_limit="-18.16" upper_limit="-0.92"/>
                    <measurement group_id="O3" value="-4.57" lower_limit="-7.29" upper_limit="-1.86"/>
                    <measurement group_id="O4" value="-19.80" lower_limit="-27.25" upper_limit="-12.35"/>
                    <measurement group_id="O5" value="-20.50" lower_limit="-28.45" upper_limit="-12.55"/>
                    <measurement group_id="O6" value="-14.88" lower_limit="-18.60" upper_limit="-11.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.42" lower_limit="-20.15" upper_limit="-12.68"/>
                    <measurement group_id="O2" value="-15.25" lower_limit="-19.85" upper_limit="-10.65"/>
                    <measurement group_id="O3" value="-8.00" lower_limit="-15.46" upper_limit="-0.54"/>
                    <measurement group_id="O4" value="-18.40" lower_limit="-26.99" upper_limit="-9.81"/>
                    <measurement group_id="O5" value="-24.92" lower_limit="-33.96" upper_limit="-15.88"/>
                    <measurement group_id="O6" value="-14.83" lower_limit="-19.21" upper_limit="-10.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.33" lower_limit="-21.05" upper_limit="-13.61"/>
                    <measurement group_id="O2" value="-12.33" lower_limit="-23.09" upper_limit="-1.58"/>
                    <measurement group_id="O3" value="-5.50" lower_limit="-14.64" upper_limit="3.64"/>
                    <measurement group_id="O4" value="-18.88" lower_limit="-28.63" upper_limit="-9.12"/>
                    <measurement group_id="O5" value="-28.88" lower_limit="-41.80" upper_limit="-15.95"/>
                    <measurement group_id="O6" value="-15.00" lower_limit="-20.10" upper_limit="-9.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.78" lower_limit="-25.14" upper_limit="-14.41"/>
                    <measurement group_id="O2" value="-19.00" lower_limit="-82.53" upper_limit="44.53"/>
                    <measurement group_id="O3" value="-11.50" lower_limit="-81.38" upper_limit="58.38"/>
                    <measurement group_id="O4" value="-20.20" lower_limit="-35.42" upper_limit="-4.98"/>
                    <measurement group_id="O5" value="-26.20" lower_limit="-36.90" upper_limit="-15.50"/>
                    <measurement group_id="O6" value="-15.50" lower_limit="-21.52" upper_limit="-9.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Participant's Assessment of Pain (Visual Analog Scale [VAS]) From Baseline of Study M16-063</title>
        <description>Participants rated their pain on a visual analogue scale (VAS) of 0 to 100 (mm), with 0 representing no pain and 100 representing the worst possible pain. Negative values indicate improvement from baseline.</description>
        <time_frame>Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763</time_frame>
        <population>Full Analysis Set: all participants who completed Study M16-063 and received at least 1 dose of assigned study drug in Study M16-763 with available data</population>
        <group_list>
          <group group_id="O1">
            <title>ABBV-599 in M16-063/ABBV-599 in M16-763</title>
            <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>ABBV-105 60 mg/UPA Placebo</title>
            <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O3">
            <title>ABBV-105 20 mg/UPA Placebo</title>
            <description>20 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O4">
            <title>ABBV-105 5 mg/UPA Placebo</title>
            <description>5 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O5">
            <title>UPA 15 mg/ABBV-105 Placebo</title>
            <description>15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks; placebo capsule for elsubrutinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O6">
            <title>Placebo in M16-063/ABBV-599 in M16-763</title>
            <description>Placebo in M16-063; 60 mg elsubrutinib capsule once a day by mouth for 48 weeks and 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks in M16-763</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Participant's Assessment of Pain (Visual Analog Scale [VAS]) From Baseline of Study M16-063</title>
          <description>Participants rated their pain on a visual analogue scale (VAS) of 0 to 100 (mm), with 0 representing no pain and 100 representing the worst possible pain. Negative values indicate improvement from baseline.</description>
          <population>Full Analysis Set: all participants who completed Study M16-063 and received at least 1 dose of assigned study drug in Study M16-763 with available data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="18"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.68" lower_limit="-62.42" upper_limit="-36.94"/>
                    <measurement group_id="O2" value="-34.67" lower_limit="-51.73" upper_limit="-17.61"/>
                    <measurement group_id="O3" value="-25.57" lower_limit="-56.51" upper_limit="5.37"/>
                    <measurement group_id="O4" value="-32.50" lower_limit="-53.25" upper_limit="-11.75"/>
                    <measurement group_id="O5" value="-56.17" lower_limit="-72.40" upper_limit="-39.93"/>
                    <measurement group_id="O6" value="-47.88" lower_limit="-76.92" upper_limit="-18.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45.46" lower_limit="-58.31" upper_limit="-32.61"/>
                    <measurement group_id="O2" value="-48.36" lower_limit="-60.60" upper_limit="-36.11"/>
                    <measurement group_id="O3" value="-29.43" lower_limit="-50.47" upper_limit="-8.39"/>
                    <measurement group_id="O4" value="-42.00" lower_limit="-61.74" upper_limit="-22.26"/>
                    <measurement group_id="O5" value="-57.76" lower_limit="-73.67" upper_limit="-41.86"/>
                    <measurement group_id="O6" value="-59.38" lower_limit="-80.35" upper_limit="-38.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.18" lower_limit="-61.90" upper_limit="-34.46"/>
                    <measurement group_id="O2" value="-40.62" lower_limit="-63.40" upper_limit="-17.83"/>
                    <measurement group_id="O3" value="-20.00" lower_limit="-48.48" upper_limit="8.48"/>
                    <measurement group_id="O4" value="-45.90" lower_limit="-70.64" upper_limit="-21.16"/>
                    <measurement group_id="O5" value="-53.63" lower_limit="-71.19" upper_limit="-36.06"/>
                    <measurement group_id="O6" value="-60.25" lower_limit="-80.74" upper_limit="-39.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.22" lower_limit="-61.84" upper_limit="-36.59"/>
                    <measurement group_id="O2" value="-47.13" lower_limit="-72.05" upper_limit="-22.20"/>
                    <measurement group_id="O3" value="-25.67" lower_limit="-120.27" upper_limit="68.94"/>
                    <measurement group_id="O4" value="-46.70" lower_limit="-63.40" upper_limit="-30.00"/>
                    <measurement group_id="O5" value="-58.83" lower_limit="-80.69" upper_limit="-36.98"/>
                    <measurement group_id="O6" value="-54.83" lower_limit="-90.68" upper_limit="-18.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-60.06" lower_limit="-72.78" upper_limit="-47.34"/>
                    <measurement group_id="O2" value="-49.00" lower_limit="-72.85" upper_limit="-25.15"/>
                    <measurement group_id="O3" value="-35.00" lower_limit="-69.15" upper_limit="-0.85"/>
                    <measurement group_id="O4" value="-56.13" lower_limit="-82.80" upper_limit="-29.45"/>
                    <measurement group_id="O5" value="-58.75" lower_limit="-82.80" upper_limit="-34.70"/>
                    <measurement group_id="O6" value="-61.50" lower_limit="-94.46" upper_limit="-28.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-54.67" lower_limit="-77.99" upper_limit="-31.34"/>
                    <measurement group_id="O2" value="-52.00" lower_limit="-522.13" upper_limit="418.13"/>
                    <measurement group_id="O3" value="-45.50" lower_limit="-140.80" upper_limit="49.80"/>
                    <measurement group_id="O4" value="-58.80" lower_limit="-73.74" upper_limit="-43.86"/>
                    <measurement group_id="O5" value="-61.00" lower_limit="-88.13" upper_limit="-33.87"/>
                    <measurement group_id="O6" value="-55.00" lower_limit="-100.36" upper_limit="-9.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Patient's Global Assessment of Disease Activity (PtGA) From Baseline of Study M16-063</title>
        <description>Participants rated their disease activity for the past 24 hours using a Patient's Global Assessment of Disease Activity Global visual analogue scale (VAS). The range is 0 to 100 mm, with 0 representing no disease activity and 100 representing severe disease activity. Negative values indicate improvement from baseline.</description>
        <time_frame>Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763</time_frame>
        <population>Full Analysis Set: all participants who completed Study M16-063 and received at least 1 dose of assigned study drug in Study M16-763 with available data</population>
        <group_list>
          <group group_id="O1">
            <title>ABBV-599 in M16-063/ABBV-599 in M16-763</title>
            <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>ABBV-105 60 mg/UPA Placebo</title>
            <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O3">
            <title>ABBV-105 20 mg/UPA Placebo</title>
            <description>20 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O4">
            <title>ABBV-105 5 mg/UPA Placebo</title>
            <description>5 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O5">
            <title>UPA 15 mg/ABBV-105 Placebo</title>
            <description>15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks; placebo capsule for elsubrutinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O6">
            <title>Placebo in M16-063/ABBV-599 in M16-763</title>
            <description>Placebo in M16-063; 60 mg elsubrutinib capsule once a day by mouth for 48 weeks and 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks in M16-763</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Patient's Global Assessment of Disease Activity (PtGA) From Baseline of Study M16-063</title>
          <description>Participants rated their disease activity for the past 24 hours using a Patient's Global Assessment of Disease Activity Global visual analogue scale (VAS). The range is 0 to 100 mm, with 0 representing no disease activity and 100 representing severe disease activity. Negative values indicate improvement from baseline.</description>
          <population>Full Analysis Set: all participants who completed Study M16-063 and received at least 1 dose of assigned study drug in Study M16-763 with available data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="18"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45.18" lower_limit="-58.36" upper_limit="-32.00"/>
                    <measurement group_id="O2" value="-34.07" lower_limit="-50.11" upper_limit="-18.03"/>
                    <measurement group_id="O3" value="-28.57" lower_limit="-61.69" upper_limit="4.55"/>
                    <measurement group_id="O4" value="-35.70" lower_limit="-56.96" upper_limit="-14.44"/>
                    <measurement group_id="O5" value="-56.56" lower_limit="-72.18" upper_limit="-40.93"/>
                    <measurement group_id="O6" value="-40.13" lower_limit="-67.21" upper_limit="-13.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.62" lower_limit="-59.37" upper_limit="-37.87"/>
                    <measurement group_id="O2" value="-45.93" lower_limit="-60.14" upper_limit="-31.72"/>
                    <measurement group_id="O3" value="-33.29" lower_limit="-59.62" upper_limit="-6.95"/>
                    <measurement group_id="O4" value="-45.20" lower_limit="-61.30" upper_limit="-29.10"/>
                    <measurement group_id="O5" value="-62.47" lower_limit="-76.09" upper_limit="-48.85"/>
                    <measurement group_id="O6" value="-58.13" lower_limit="-74.96" upper_limit="-41.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.18" lower_limit="-60.77" upper_limit="-31.60"/>
                    <measurement group_id="O2" value="-39.69" lower_limit="-61.63" upper_limit="-17.76"/>
                    <measurement group_id="O3" value="-21.40" lower_limit="-57.54" upper_limit="14.74"/>
                    <measurement group_id="O4" value="-45.20" lower_limit="-67.27" upper_limit="-23.13"/>
                    <measurement group_id="O5" value="-56.31" lower_limit="-71.70" upper_limit="-40.92"/>
                    <measurement group_id="O6" value="-57.75" lower_limit="-75.80" upper_limit="-39.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-51.70" lower_limit="-64.00" upper_limit="-39.39"/>
                    <measurement group_id="O2" value="-48.63" lower_limit="-73.95" upper_limit="-23.30"/>
                    <measurement group_id="O3" value="-31.67" lower_limit="-141.65" upper_limit="78.32"/>
                    <measurement group_id="O4" value="-46.20" lower_limit="-64.52" upper_limit="-27.88"/>
                    <measurement group_id="O5" value="-61.00" lower_limit="-81.17" upper_limit="-40.83"/>
                    <measurement group_id="O6" value="-53.33" lower_limit="-84.24" upper_limit="-22.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-54.24" lower_limit="-69.66" upper_limit="-38.81"/>
                    <measurement group_id="O2" value="-44.00" lower_limit="-71.07" upper_limit="-16.93"/>
                    <measurement group_id="O3" value="-38.67" lower_limit="-88.62" upper_limit="11.28"/>
                    <measurement group_id="O4" value="-53.13" lower_limit="-76.82" upper_limit="-29.43"/>
                    <measurement group_id="O5" value="-60.75" lower_limit="-84.13" upper_limit="-37.37"/>
                    <measurement group_id="O6" value="-56.67" lower_limit="-84.14" upper_limit="-29.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-56.67" lower_limit="-83.18" upper_limit="-30.16"/>
                    <measurement group_id="O2" value="-56.00" lower_limit="-462.60" upper_limit="350.60"/>
                    <measurement group_id="O3" value="-54.50" lower_limit="-226.03" upper_limit="117.03"/>
                    <measurement group_id="O4" value="-54.60" lower_limit="-70.61" upper_limit="-38.59"/>
                    <measurement group_id="O5" value="-59.80" lower_limit="-96.50" upper_limit="-23.10"/>
                    <measurement group_id="O6" value="-57.00" lower_limit="-87.75" upper_limit="-26.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Physician's Global Assessment of Disease Activity (PhGA) From Baseline of Study M16-063</title>
        <description>The physician assessed a participant's disease activity at the time of the visit using a Physician's Global Assessment of Disease visual analogue scale (VAS). The range is 0 to 100 mm, with 0 representing no disease activity and 100 representing severe disease activity. Negative values indicate improvement from baseline.</description>
        <time_frame>Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763</time_frame>
        <population>Full Analysis Set: all participants who completed Study M16-063 and received at least 1 dose of assigned study drug in Study M16-763 with available data</population>
        <group_list>
          <group group_id="O1">
            <title>ABBV-599 in M16-063/ABBV-599 in M16-763</title>
            <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>ABBV-105 60 mg/UPA Placebo</title>
            <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O3">
            <title>ABBV-105 20 mg/UPA Placebo</title>
            <description>20 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O4">
            <title>ABBV-105 5 mg/UPA Placebo</title>
            <description>5 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O5">
            <title>UPA 15 mg/ABBV-105 Placebo</title>
            <description>15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks; placebo capsule for elsubrutinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O6">
            <title>Placebo in M16-063/ABBV-599 in M16-763</title>
            <description>Placebo in M16-063; 60 mg elsubrutinib capsule once a day by mouth for 48 weeks and 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks in M16-763</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Physician's Global Assessment of Disease Activity (PhGA) From Baseline of Study M16-063</title>
          <description>The physician assessed a participant's disease activity at the time of the visit using a Physician's Global Assessment of Disease visual analogue scale (VAS). The range is 0 to 100 mm, with 0 representing no disease activity and 100 representing severe disease activity. Negative values indicate improvement from baseline.</description>
          <population>Full Analysis Set: all participants who completed Study M16-063 and received at least 1 dose of assigned study drug in Study M16-763 with available data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="17"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-57.22" lower_limit="-65.56" upper_limit="-48.87"/>
                    <measurement group_id="O2" value="-41.00" lower_limit="-53.42" upper_limit="-28.58"/>
                    <measurement group_id="O3" value="-33.00" lower_limit="-61.23" upper_limit="-4.77"/>
                    <measurement group_id="O4" value="-35.00" lower_limit="-59.98" upper_limit="-10.02"/>
                    <measurement group_id="O5" value="-59.06" lower_limit="-69.39" upper_limit="-48.72"/>
                    <measurement group_id="O6" value="-55.13" lower_limit="-82.03" upper_limit="-28.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-57.93" lower_limit="-65.61" upper_limit="-50.25"/>
                    <measurement group_id="O2" value="-48.36" lower_limit="-60.05" upper_limit="-36.66"/>
                    <measurement group_id="O3" value="-39.43" lower_limit="-70.88" upper_limit="-7.98"/>
                    <measurement group_id="O4" value="-50.89" lower_limit="-68.36" upper_limit="-33.42"/>
                    <measurement group_id="O5" value="-61.19" lower_limit="-71.90" upper_limit="-50.47"/>
                    <measurement group_id="O6" value="-62.38" lower_limit="-77.73" upper_limit="-47.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-55.04" lower_limit="-64.27" upper_limit="-45.82"/>
                    <measurement group_id="O2" value="-41.23" lower_limit="-57.85" upper_limit="-24.61"/>
                    <measurement group_id="O3" value="-41.80" lower_limit="-60.33" upper_limit="-23.27"/>
                    <measurement group_id="O4" value="-54.78" lower_limit="-71.11" upper_limit="-38.45"/>
                    <measurement group_id="O5" value="-56.20" lower_limit="-73.22" upper_limit="-39.18"/>
                    <measurement group_id="O6" value="-63.50" lower_limit="-79.15" upper_limit="-47.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-57.55" lower_limit="-66.96" upper_limit="-48.13"/>
                    <measurement group_id="O2" value="-53.75" lower_limit="-70.49" upper_limit="-37.01"/>
                    <measurement group_id="O3" value="-60.00" lower_limit="-112.58" upper_limit="-7.42"/>
                    <measurement group_id="O4" value="-54.78" lower_limit="-73.97" upper_limit="-35.58"/>
                    <measurement group_id="O5" value="-68.45" lower_limit="-81.66" upper_limit="-55.25"/>
                    <measurement group_id="O6" value="-65.83" lower_limit="-89.60" upper_limit="-42.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-56.39" lower_limit="-71.53" upper_limit="-41.24"/>
                    <measurement group_id="O2" value="-36.83" lower_limit="-75.18" upper_limit="1.52"/>
                    <measurement group_id="O3" value="-56.67" lower_limit="-93.29" upper_limit="-20.04"/>
                    <measurement group_id="O4" value="-57.14" lower_limit="-80.22" upper_limit="-34.07"/>
                    <measurement group_id="O5" value="-66.13" lower_limit="-82.33" upper_limit="-49.92"/>
                    <measurement group_id="O6" value="-66.40" lower_limit="-89.67" upper_limit="-43.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-64.33" lower_limit="-79.18" upper_limit="-49.48"/>
                    <measurement group_id="O2" value="-56.00" lower_limit="-437.19" upper_limit="325.19"/>
                    <measurement group_id="O3" value="-65.00" lower_limit="-141.24" upper_limit="11.24"/>
                    <measurement group_id="O4" value="-61.50" lower_limit="-88.83" upper_limit="-34.17"/>
                    <measurement group_id="O5" value="-60.00" lower_limit="-88.34" upper_limit="-31.66"/>
                    <measurement group_id="O6" value="-56.75" lower_limit="-87.94" upper_limit="-25.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Health Assessment Questionnaire Disability Index (HAQ-DI) From Baseline of Study M16-063</title>
        <description>The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from baseline in the overall score indicates improvement.</description>
        <time_frame>Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763</time_frame>
        <population>Full Analysis Set: all participants who completed Study M16-063 and received at least 1 dose of assigned study drug in Study M16-763 with available data</population>
        <group_list>
          <group group_id="O1">
            <title>ABBV-599 in M16-063/ABBV-599 in M16-763</title>
            <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>ABBV-105 60 mg/UPA Placebo</title>
            <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O3">
            <title>ABBV-105 20 mg/UPA Placebo</title>
            <description>20 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O4">
            <title>ABBV-105 5 mg/UPA Placebo</title>
            <description>5 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O5">
            <title>UPA 15 mg/ABBV-105 Placebo</title>
            <description>15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks; placebo capsule for elsubrutinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O6">
            <title>Placebo in M16-063/ABBV-599 in M16-763</title>
            <description>Placebo in M16-063; 60 mg elsubrutinib capsule once a day by mouth for 48 weeks and 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks in M16-763</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Health Assessment Questionnaire Disability Index (HAQ-DI) From Baseline of Study M16-063</title>
          <description>The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from baseline in the overall score indicates improvement.</description>
          <population>Full Analysis Set: all participants who completed Study M16-063 and received at least 1 dose of assigned study drug in Study M16-763 with available data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="17"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" lower_limit="-0.84" upper_limit="-0.29"/>
                    <measurement group_id="O2" value="-0.49" lower_limit="-0.84" upper_limit="-0.14"/>
                    <measurement group_id="O3" value="-0.61" lower_limit="-1.27" upper_limit="0.06"/>
                    <measurement group_id="O4" value="-0.61" lower_limit="-1.04" upper_limit="-0.19"/>
                    <measurement group_id="O5" value="-0.85" lower_limit="-1.21" upper_limit="-0.50"/>
                    <measurement group_id="O6" value="-0.47" lower_limit="-0.77" upper_limit="-0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" lower_limit="-0.81" upper_limit="-0.36"/>
                    <measurement group_id="O2" value="-0.46" lower_limit="-0.80" upper_limit="-0.12"/>
                    <measurement group_id="O3" value="-0.57" lower_limit="-1.24" upper_limit="0.09"/>
                    <measurement group_id="O4" value="-0.54" lower_limit="-0.98" upper_limit="-0.09"/>
                    <measurement group_id="O5" value="-0.59" lower_limit="-0.94" upper_limit="-0.25"/>
                    <measurement group_id="O6" value="-0.78" lower_limit="-1.29" upper_limit="-0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.64" lower_limit="-0.91" upper_limit="-0.36"/>
                    <measurement group_id="O2" value="-0.45" lower_limit="-0.93" upper_limit="0.03"/>
                    <measurement group_id="O3" value="-0.15" lower_limit="-0.45" upper_limit="0.15"/>
                    <measurement group_id="O4" value="-0.51" lower_limit="-0.94" upper_limit="-0.09"/>
                    <measurement group_id="O5" value="-0.73" lower_limit="-1.10" upper_limit="-0.35"/>
                    <measurement group_id="O6" value="-0.75" lower_limit="-1.17" upper_limit="-0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.67" lower_limit="-0.95" upper_limit="-0.38"/>
                    <measurement group_id="O2" value="-0.70" lower_limit="-1.45" upper_limit="0.05"/>
                    <measurement group_id="O3" value="-0.33" lower_limit="-0.81" upper_limit="0.14"/>
                    <measurement group_id="O4" value="-0.30" lower_limit="-0.70" upper_limit="0.10"/>
                    <measurement group_id="O5" value="-0.51" lower_limit="-0.94" upper_limit="-0.09"/>
                    <measurement group_id="O6" value="-0.56" lower_limit="-1.05" upper_limit="-0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" lower_limit="-1.06" upper_limit="-0.34"/>
                    <measurement group_id="O2" value="-0.63" lower_limit="-1.76" upper_limit="0.51"/>
                    <measurement group_id="O3" value="-0.29" lower_limit="-0.65" upper_limit="0.07"/>
                    <measurement group_id="O4" value="-0.42" lower_limit="-0.90" upper_limit="0.06"/>
                    <measurement group_id="O5" value="-0.39" lower_limit="-0.83" upper_limit="0.05"/>
                    <measurement group_id="O6" value="-0.71" lower_limit="-1.17" upper_limit="-0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.78" lower_limit="-1.22" upper_limit="-0.34"/>
                    <measurement group_id="O2" value="-0.75" lower_limit="-13.46" upper_limit="11.96"/>
                    <measurement group_id="O3" value="-0.31" lower_limit="-4.28" upper_limit="3.66"/>
                    <measurement group_id="O4" value="-0.58" lower_limit="-1.30" upper_limit="0.15"/>
                    <measurement group_id="O5" value="-0.48" lower_limit="-1.77" upper_limit="0.82"/>
                    <measurement group_id="O6" value="-0.72" lower_limit="-1.61" upper_limit="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in High-Sensitivity C-Reactive Protein (Hs-CRP) From Baseline of Study M16-063</title>
        <description>C-reactive protein is a blood test marker for inflammation in the body, and levels rise in response to inflammation. A negative change from baseline indicates improvement.</description>
        <time_frame>Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763</time_frame>
        <population>Full Analysis Set: all participants who completed Study M16-063 and received at least 1 dose of assigned study drug in Study M16-763 with available data</population>
        <group_list>
          <group group_id="O1">
            <title>ABBV-599 in M16-063/ABBV-599 in M16-763</title>
            <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>ABBV-105 60 mg/UPA Placebo</title>
            <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O3">
            <title>ABBV-105 20 mg/UPA Placebo</title>
            <description>20 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O4">
            <title>ABBV-105 5 mg/UPA Placebo</title>
            <description>5 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O5">
            <title>UPA 15 mg/ABBV-105 Placebo</title>
            <description>15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks; placebo capsule for elsubrutinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O6">
            <title>Placebo in M16-063/ABBV-599 in M16-763</title>
            <description>Placebo in M16-063; 60 mg elsubrutinib capsule once a day by mouth for 48 weeks and 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks in M16-763</description>
          </group>
        </group_list>
        <measure>
          <title>Change in High-Sensitivity C-Reactive Protein (Hs-CRP) From Baseline of Study M16-063</title>
          <description>C-reactive protein is a blood test marker for inflammation in the body, and levels rise in response to inflammation. A negative change from baseline indicates improvement.</description>
          <population>Full Analysis Set: all participants who completed Study M16-063 and received at least 1 dose of assigned study drug in Study M16-763 with available data</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="20"/>
                    <count group_id="O6" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.04" lower_limit="-24.13" upper_limit="-7.95"/>
                    <measurement group_id="O2" value="5.34" lower_limit="-9.84" upper_limit="20.53"/>
                    <measurement group_id="O3" value="-0.96" lower_limit="-6.20" upper_limit="4.28"/>
                    <measurement group_id="O4" value="-14.85" lower_limit="-34.27" upper_limit="4.57"/>
                    <measurement group_id="O5" value="-11.48" lower_limit="-16.88" upper_limit="-6.07"/>
                    <measurement group_id="O6" value="-10.00" lower_limit="-28.36" upper_limit="8.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.08" lower_limit="-23.26" upper_limit="-6.90"/>
                    <measurement group_id="O2" value="-0.20" lower_limit="-15.16" upper_limit="14.76"/>
                    <measurement group_id="O3" value="-2.18" lower_limit="-4.30" upper_limit="-0.06"/>
                    <measurement group_id="O4" value="-15.09" lower_limit="-38.53" upper_limit="8.34"/>
                    <measurement group_id="O5" value="-9.48" lower_limit="-15.35" upper_limit="-3.60"/>
                    <measurement group_id="O6" value="-13.16" lower_limit="-32.31" upper_limit="5.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.61" lower_limit="-27.35" upper_limit="-5.88"/>
                    <measurement group_id="O2" value="-6.00" lower_limit="-24.37" upper_limit="12.36"/>
                    <measurement group_id="O3" value="-1.66" lower_limit="-4.91" upper_limit="1.59"/>
                    <measurement group_id="O4" value="-17.11" lower_limit="-44.18" upper_limit="9.95"/>
                    <measurement group_id="O5" value="-9.55" lower_limit="-14.24" upper_limit="-4.85"/>
                    <measurement group_id="O6" value="-16.22" lower_limit="-28.83" upper_limit="-3.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.88" lower_limit="-23.43" upper_limit="-4.32"/>
                    <measurement group_id="O2" value="-12.43" lower_limit="-27.58" upper_limit="2.73"/>
                    <measurement group_id="O3" value="-1.58" lower_limit="-11.33" upper_limit="8.18"/>
                    <measurement group_id="O4" value="-13.61" lower_limit="-34.50" upper_limit="7.28"/>
                    <measurement group_id="O5" value="-7.76" lower_limit="-13.95" upper_limit="-1.56"/>
                    <measurement group_id="O6" value="-18.34" lower_limit="-37.30" upper_limit="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.41" lower_limit="-28.14" upper_limit="-4.69"/>
                    <measurement group_id="O2" value="-18.38" lower_limit="-50.37" upper_limit="13.60"/>
                    <measurement group_id="O3" value="-5.99" lower_limit="-17.43" upper_limit="5.45"/>
                    <measurement group_id="O4" value="-20.18" lower_limit="-49.36" upper_limit="9.00"/>
                    <measurement group_id="O5" value="-7.22" lower_limit="-14.57" upper_limit="0.14"/>
                    <measurement group_id="O6" value="-18.30" lower_limit="-36.16" upper_limit="-0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.69" lower_limit="-45.41" upper_limit="-5.98"/>
                    <measurement group_id="O2" value="-31.46" lower_limit="-288.63" upper_limit="225.71"/>
                    <measurement group_id="O3" value="-3.98" lower_limit="-116.05" upper_limit="108.09"/>
                    <measurement group_id="O4" value="-25.58" lower_limit="-67.98" upper_limit="16.83"/>
                    <measurement group_id="O5" value="-3.34" lower_limit="-23.18" upper_limit="16.50"/>
                    <measurement group_id="O6" value="-12.47" lower_limit="-33.61" upper_limit="8.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Morning Stiffness Severity From Baseline of Study M16-063</title>
        <description>Morning stiffness severity was assessed by a numeric rating-scale (NRS). Participants rated the severity of morning stiffness during the past week from 0 to 10 with 0 representing &quot;not severe&quot; and 10 &quot;very severe&quot;. Negative values indicate improvement from baseline.</description>
        <time_frame>Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763</time_frame>
        <population>Full Analysis Set: all participants who completed Study M16-063 and received at least 1 dose of assigned study drug in Study M16-763 with available data</population>
        <group_list>
          <group group_id="O1">
            <title>ABBV-599 in M16-063/ABBV-599 in M16-763</title>
            <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>ABBV-105 60 mg/UPA Placebo</title>
            <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O3">
            <title>ABBV-105 20 mg/UPA Placebo</title>
            <description>20 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O4">
            <title>ABBV-105 5 mg/UPA Placebo</title>
            <description>5 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O5">
            <title>UPA 15 mg/ABBV-105 Placebo</title>
            <description>15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks; placebo capsule for elsubrutinib once a day by mouth for 48 weeks</description>
          </group>
          <group group_id="O6">
            <title>Placebo in M16-063/ABBV-599 in M16-763</title>
            <description>Placebo in M16-063; 60 mg elsubrutinib capsule once a day by mouth for 48 weeks and 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks in M16-763</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Morning Stiffness Severity From Baseline of Study M16-063</title>
          <description>Morning stiffness severity was assessed by a numeric rating-scale (NRS). Participants rated the severity of morning stiffness during the past week from 0 to 10 with 0 representing &quot;not severe&quot; and 10 &quot;very severe&quot;. Negative values indicate improvement from baseline.</description>
          <population>Full Analysis Set: all participants who completed Study M16-063 and received at least 1 dose of assigned study drug in Study M16-763 with available data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="17"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.27" lower_limit="-5.56" upper_limit="-2.99"/>
                    <measurement group_id="O2" value="-2.27" lower_limit="-3.69" upper_limit="-0.84"/>
                    <measurement group_id="O3" value="-2.14" lower_limit="-4.99" upper_limit="0.70"/>
                    <measurement group_id="O4" value="-3.40" lower_limit="-6.02" upper_limit="-0.78"/>
                    <measurement group_id="O5" value="-5.29" lower_limit="-6.54" upper_limit="-4.05"/>
                    <measurement group_id="O6" value="-2.38" lower_limit="-4.65" upper_limit="-0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.48" lower_limit="-5.52" upper_limit="-3.44"/>
                    <measurement group_id="O2" value="-2.64" lower_limit="-3.81" upper_limit="-1.47"/>
                    <measurement group_id="O3" value="-3.29" lower_limit="-5.89" upper_limit="-0.69"/>
                    <measurement group_id="O4" value="-3.70" lower_limit="-5.21" upper_limit="-2.19"/>
                    <measurement group_id="O5" value="-4.88" lower_limit="-6.43" upper_limit="-3.32"/>
                    <measurement group_id="O6" value="-3.50" lower_limit="-5.50" upper_limit="-1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.36" lower_limit="-5.83" upper_limit="-2.90"/>
                    <measurement group_id="O2" value="-2.23" lower_limit="-4.28" upper_limit="-0.18"/>
                    <measurement group_id="O3" value="-1.20" lower_limit="-2.82" upper_limit="0.42"/>
                    <measurement group_id="O4" value="-4.20" lower_limit="-5.66" upper_limit="-2.74"/>
                    <measurement group_id="O5" value="-4.53" lower_limit="-5.75" upper_limit="-3.32"/>
                    <measurement group_id="O6" value="-3.13" lower_limit="-5.55" upper_limit="-0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.43" lower_limit="-5.95" upper_limit="-2.92"/>
                    <measurement group_id="O2" value="-3.38" lower_limit="-5.74" upper_limit="-1.01"/>
                    <measurement group_id="O3" value="-1.00" lower_limit="-5.30" upper_limit="3.30"/>
                    <measurement group_id="O4" value="-4.00" lower_limit="-5.39" upper_limit="-2.61"/>
                    <measurement group_id="O5" value="-5.55" lower_limit="-6.80" upper_limit="-4.29"/>
                    <measurement group_id="O6" value="-3.00" lower_limit="-6.18" upper_limit="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.47" lower_limit="-6.64" upper_limit="-4.30"/>
                    <measurement group_id="O2" value="-3.33" lower_limit="-6.49" upper_limit="-0.17"/>
                    <measurement group_id="O3" value="-1.00" lower_limit="-7.57" upper_limit="5.57"/>
                    <measurement group_id="O4" value="-4.13" lower_limit="-6.67" upper_limit="-1.58"/>
                    <measurement group_id="O5" value="-5.38" lower_limit="-7.10" upper_limit="-3.65"/>
                    <measurement group_id="O6" value="-3.67" lower_limit="-6.90" upper_limit="-0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.89" lower_limit="-6.54" upper_limit="-3.24"/>
                    <measurement group_id="O2" value="-4.50" lower_limit="-23.56" upper_limit="14.56"/>
                    <measurement group_id="O3" value="-3.00" lower_limit="NA" upper_limit="NA">Not calculable/estimable because standard deviation = 0</measurement>
                    <measurement group_id="O4" value="-4.40" lower_limit="-6.66" upper_limit="-2.14"/>
                    <measurement group_id="O5" value="-4.80" lower_limit="-7.19" upper_limit="-2.41"/>
                    <measurement group_id="O6" value="-3.00" lower_limit="-5.25" upper_limit="-0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All-cause mortality is reported from enrollment to the end of study; median time on follow-up was ABBV-599 in M16-063/M16-763 (279 days); ABBV-105 60 mg/UPA placebo (183 days); ABBV-105 20 mg/UPA placebo (159 days); ABBV-105 5 mg/UPA placebo (337 days); UPA 15 mg/ABBV-105 placebo (229 days); and Placebo in M16-063/ABBV-599 in M16-763 (281 days). TEAEs/SAEs were collected from the first dose in M16-763 until 30 days after last dose, up to 52 weeks.</time_frame>
      <desc>All-cause mortality and adverse events: all participants who completed Study M16-063 and received at least one dose of assigned study drug in Study M16-763, grouped according to treatments actually received in Study M16-763</desc>
      <group_list>
        <group group_id="E1">
          <title>ABBV-599 in M16-063/ABBV-599 in M16-763</title>
          <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks</description>
        </group>
        <group group_id="E2">
          <title>ABBV-105 60 mg/UPA Placebo</title>
          <description>60 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
        </group>
        <group group_id="E3">
          <title>ABBV-105 20 mg/UPA Placebo</title>
          <description>20 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
        </group>
        <group group_id="E4">
          <title>ABBV-105 5 mg/UPA Placebo</title>
          <description>5 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks</description>
        </group>
        <group group_id="E5">
          <title>UPA 15 mg/ABBV-105 Placebo</title>
          <description>15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks; placebo capsule for elsubrutinib once a day by mouth for 48 weeks</description>
        </group>
        <group group_id="E6">
          <title>Placebo in M16-063/ABBV-599 in M16-763</title>
          <description>Placebo in M16-063; 60 mg elsubrutinib capsule once a day by mouth for 48 weeks and 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks in M16-763</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>PERIPROSTHETIC FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>LUNG ADENOCARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>MICROCYTIC ANAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>DRUG INTOLERANCE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>DRUG WITHDRAWAL SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>EAR INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>ORAL CANDIDIASIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION VIRAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>TOOTH INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>URETHRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>URINE ANALYSIS ABNORMAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>JOINT SWELLING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>RHEUMATOID ARTHRITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>TREMOR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL CYST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DERMATITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>AbbVie</organization>
      <phone>800-633-9110</phone>
      <email>abbvieclinicaltrials@abbvie.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03823378
org study id: M16-763
secondary id: 2018-002306-31
nct id: NCT03823378
lead sponsor: 
has dmc: Yes
is fda regulated drug: Yes
is fda regulated device: No
is us export: Yes
This was a long-term extension (LTE) study to assess the safety, tolerability, and efficacy
      of ABBV-105 (elsubrutinib [ELS]) and ABBV-599 (ELS 60 mg and upadacitinib [UPA] 15 mg) in
      participants with rheumatoid arthritis (RA) who completed Study M16-063 (NCT03682705).
This was a Phase 2, double-blind, multicenter, long-term extension (LTE) study to assess the
      safety, tolerability, and efficacy of 3 doses of ABBV-105 (elsubrutinib [ELS] 5 mg, 20 mg,
      and 60 mg) and ABBV-599 (ELS 60 mg and upadacitinib [UPA] 15 mg) in adults with active
      rheumatoid arthritis with inadequate response or intolerance to biologic disease-modifying
      antirheumatic drugs (bDMARDs). Participants who successfully completed treatment in the
      feeder Study M16-063, a Phase 2 dose exploratory study, were eligible to participate in this
      study. Those who met eligibility criteria and entered this study receiving ELS, ABBV-599, or
      UPA from Study M16-063 continued on their previously assigned treatment through termination
      of this study. Participants originally randomized to placebo in Study M16-063 rolled over to
      ABBV-599 in a blinded fashion in this study.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
measure: Number of Participants With Adverse Events (AEs)
time frame: On or after the first dose of study drug in Study M16-763, and up to 30 days after the last dose of study drug in Study M16-763, up to 52 weeks
description: An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug as either having a reasonable possibility or no reasonable possibility. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug.
measure: Change in Disease Activity Score 28 C-reactive Protein (DAS28-CRP) From Baseline of Study M16-063 at Each Study Visit in Study M16-763
time frame: Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
description: The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from Baseline indicates improvement in disease activity.
measure: Percentage of Participants Achieving Low Disease Activity (LDA) Based on Disease Activity Score 28 C-reactive Protein (DAS28-CRP)
time frame: Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
description: The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. Low Disease Activity (LDA) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) of less than or equal to 3.2.
measure: Percentage of Participants Achieving Clinical Remission (CR) Based on Disease Activity Score 28 C-reactive Protein (DAS28-CRP)
time frame: Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
description: The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. Clinical Remission (CR) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) of less than 2.6.
measure: Change in Clinical Disease Activity Index (CDAI) From Baseline of Study M16-063
time frame: Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
description: The CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. A negative change from Baseline indicates improvement in disease activity.
measure: Percentage of Participants Achieving Low Disease Activity (LDA) Based on Clinical Disease Activity Index (CDAI) Criteria
time frame: Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
description: The CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. Low Disease Activity (LDA) based on CDAI is defined as achieving a total CDAI score of less than or equal to 10.
measure: Percentage of Participants Achieving Clinical Remission (CR) Based on Clinical Disease Activity Index (CDAI) Criteria
time frame: Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
description: The CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. Complete Remission (CR) based on CDAI is defined as achieving a total CDAI score of less than or equal to 2.8.
measure: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response
time frame: Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
description: Participants who met the following 3 conditions for improvement from baseline of Study M16-063 were classified as meeting the American College of Rheumatology 20% response (ACR20) criteria:
≥ 20% improvement in 68-tender joint count from Baseline of Study M16-063
≥ 20% improvement in 66-swollen joint count from Baseline of Study M16-063 and
≥ 20% improvement in at least 3 of the 5 following parameters from Baseline of Study M16-063:
Patient's Assessment of Pain (Visual Analog Scale [VAS])
Patient's Global Assessment of Disease Activity (PtGA)
Physician's Global Assessment of Disease Activity (PhGA)
Health Assessment Questionnaire Disability Index (HAQ-DI)
High-sensitivity C-reactive protein (hsCRP)
measure: Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response
time frame: Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
description: Participants who met the following 3 conditions for improvement from baseline of Study M16-063 were classified as meeting the American College of Rheumatology 50% response (ACR50) criteria:
≥ 50% improvement in 68-tender joint count from Baseline of Study M16-063
≥ 50% improvement in 66-swollen joint count from Baseline of Study M16-063 and
≥ 50% improvement in at least 3 of the 5 following parameters from Baseline of Study M16-063:
Patient's Assessment of Pain (Visual Analog Scale [VAS])
Patient's Global Assessment of Disease Activity (PtGA)
Physician's Global Assessment of Disease Activity (PhGA)
Health Assessment Questionnaire Disability Index (HAQ-DI)
High-sensitivity C-reactive protein (hsCRP)
measure: Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response
time frame: Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
description: Participants who met the following 3 conditions for improvement from baseline of Study M16-063 were classified as meeting the American College of Rheumatology 70% response (ACR70) criteria:
≥ 70% improvement in 68-tender joint count from Baseline of Study M16-063
≥ 70% improvement in 66-swollen joint count from Baseline of Study M16-063 and
≥ 70% improvement in at least 3 of the 5 following parameters from Baseline of Study M16-063:
Patient's Assessment of Pain (Visual Analog Scale [VAS])
Patient's Global Assessment of Disease Activity (PtGA)
Physician's Global Assessment of Disease Activity (PhGA)
Health Assessment Questionnaire Disability Index (HAQ-DI)
High-sensitivity C-reactive protein (hsCRP)
measure: Change in Swollen Joint Count 66 (SJC66) From Baseline of Study M16-063
time frame: Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
description: Sixty-six joints were assessed for swelling by physical examination. Swelling of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with swelling) to 66 (worst possible score/66 joints with swelling). Negative values indicate improvement from baseline.
measure: Change in Tender Joint Count 68 (TJC68) From Baseline of Study M16-063
time frame: Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
description: Sixty-eight joints were assessed for tenderness by physical examination. Pain or tenderness of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with tenderness) to 68 (worst possible score/68 joints with tenderness). Negative values indicate improvement from baseline.
measure: Change in Participant's Assessment of Pain (Visual Analog Scale [VAS]) From Baseline of Study M16-063
time frame: Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
description: Participants rated their pain on a visual analogue scale (VAS) of 0 to 100 (mm), with 0 representing no pain and 100 representing the worst possible pain. Negative values indicate improvement from baseline.
measure: Change in Patient's Global Assessment of Disease Activity (PtGA) From Baseline of Study M16-063
time frame: Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
description: Participants rated their disease activity for the past 24 hours using a Patient's Global Assessment of Disease Activity Global visual analogue scale (VAS). The range is 0 to 100 mm, with 0 representing no disease activity and 100 representing severe disease activity. Negative values indicate improvement from baseline.
measure: Change in Physician's Global Assessment of Disease Activity (PhGA) From Baseline of Study M16-063
time frame: Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
description: The physician assessed a participant's disease activity at the time of the visit using a Physician's Global Assessment of Disease visual analogue scale (VAS). The range is 0 to 100 mm, with 0 representing no disease activity and 100 representing severe disease activity. Negative values indicate improvement from baseline.
measure: Change in Health Assessment Questionnaire Disability Index (HAQ-DI) From Baseline of Study M16-063
time frame: Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
description: The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from baseline in the overall score indicates improvement.
measure: Change in High-Sensitivity C-Reactive Protein (Hs-CRP) From Baseline of Study M16-063
time frame: Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
description: C-reactive protein is a blood test marker for inflammation in the body, and levels rise in response to inflammation. A negative change from baseline indicates improvement.
measure: Change in Morning Stiffness Severity From Baseline of Study M16-063
time frame: Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
description: Morning stiffness severity was assessed by a numeric rating-scale (NRS). Participants rated the severity of morning stiffness during the past week from 0 to 10 with 0 representing "not severe" and 10 "very severe". Negative values indicate improvement from baseline.
arm group label: ABBV-599 in M16-063/ABBV-599 in M16-763
arm group type: Experimental
description: 60 mg elsubrutinib capsule once a day by mouth for 48 weeks; 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks
arm group label: ABBV-105 60 mg/UPA placebo
arm group type: Experimental
description: 60 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks
arm group label: ABBV-105 20 mg/UPA placebo
arm group type: Experimental
description: 20 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks
arm group label: ABBV-105 5 mg/UPA placebo
arm group type: Experimental
description: 5 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks
arm group label: UPA 15 mg/ABBV-105 placebo
arm group type: Experimental
description: 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks; placebo capsule for elsubrutinib once a day by mouth for 48 weeks
arm group label: Placebo in M16-063/ABBV-599 in M16-763
arm group type: Experimental
description: Placebo in M16-063; 60 mg elsubrutinib capsule once a day by mouth for 48 weeks and 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks in M16-763
intervention type: Drug
intervention name: Elsubrutinib
description: Elsubrutinib capsule will be administered orally.
arm group label: ABBV-105 20 mg/UPA placebo
arm group label: ABBV-105 5 mg/UPA placebo
arm group label: ABBV-105 60 mg/UPA placebo
arm group label: ABBV-599 in M16-063/ABBV-599 in M16-763
arm group label: Placebo in M16-063/ABBV-599 in M16-763
other name: ABBV-105
intervention type: Drug
intervention name: Upadacitinib
description: Upadacitinib tablet will be administered orally.
arm group label: ABBV-599 in M16-063/ABBV-599 in M16-763
arm group label: Placebo in M16-063/ABBV-599 in M16-763
arm group label: UPA 15 mg/ABBV-105 placebo
other name: ABT-494
intervention type: Drug
intervention name: Placebo for elsubrutinib
description: Placebo capsule for elsubrutinib will be administered orally.
arm group label: UPA 15 mg/ABBV-105 placebo
intervention type: Drug
intervention name: Placebo for upadacitinib
description: Upadacitinib placebo tablet will be administered orally.
arm group label: ABBV-105 20 mg/UPA placebo
arm group label: ABBV-105 5 mg/UPA placebo
arm group label: ABBV-105 60 mg/UPA placebo
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: AbbVie Inc.
role: Study Director
affiliation: AbbVie
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: Belgium
country: Canada
country: Czechia
country: Hungary
country: Poland
country: Spain
country: United Kingdom
url: https://www.rxabbvie.com/
description: Related Info.
responsible party type: Sponsor
mesh term: Arthritis
mesh term: Arthritis, Rheumatoid
mesh term: Upadacitinib
sharing ipd: Yes
ipd description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
ipd info type: Study Protocol
ipd info type: Statistical Analysis Plan (SAP)
ipd info type: Clinical Study Report (CSR)
ipd time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
ipd access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
ipd url: https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html
provided document: 
provided document: 
participant flow: 
baseline: 
outcome list: 
reported events: 
certain agreements: 
point of contact: 